Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20070278720 A1
Publication typeApplication
Application numberUS 11/725,630
Publication date6 Dec 2007
Filing date19 Mar 2007
Priority date30 May 2006
Also published asEP2032070A2, US7959940, US8192665, US8309114, US8377356, US8512735, US8613877, US8999369, US20070282431, US20110060073, US20110207843, US20120228810, US20130041065, US20130134620, US20130324636, US20140121294, WO2007142752A2, WO2007142752A3
Publication number11725630, 725630, US 2007/0278720 A1, US 2007/278720 A1, US 20070278720 A1, US 20070278720A1, US 2007278720 A1, US 2007278720A1, US-A1-20070278720, US-A1-2007278720, US2007/0278720A1, US2007/278720A1, US20070278720 A1, US20070278720A1, US2007278720 A1, US2007278720A1
InventorsYunbing Wang, David Gale
Original AssigneeYunbing Wang, Gale David C
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Implantable medical devices made from polymer-bioceramic composite
US 20070278720 A1
Abstract
Methods and devices relating to polymer-bioceramic composite implantable medical devices are disclosed.
Images(10)
Previous page
Next page
Claims(47)
1. A method of fabricating an implantable medical device comprising:
processing a plurality of agglomerated bioceramic particles with a non-reactive surface modifier, the non-reactive surface modifier reducing the agglomeration;
forming a composite with the processed bioceramic particles, the composite including the processed bioceramic particles dispersed within a polymer; and
fabricating an implantable medical device from the composite.
2. The method according to claim 1, wherein the non-reactive surface modifier lowers the surface energy of the particles.
3. The method according to claim 1, wherein the processing comprises dispersing the bioceramic particles in a solution including the non-reactive surface modifier.
4. The method according to claim 1, wherein the processing comprises mixing a suspension having the non-reactive surface modifier and the plurality of bioceramic particles so that the agglomeration is reduced.
5. The method according to claim 1, wherein forming the composite comprises processing a mixture of the polymer and the processed particles with a shear stress higher than the fracture strength of clusters of agglomerated bioceramic particles so that agglomeration is further reduced.
6. The method according to claim 1, wherein forming the composite comprises processing a mixture of the polymer and the processed particles with a twin-screw extruder or a kneader in such a way that agglomeration is further reduced.
7. The method according to claim 1, wherein the non-reactive surface modifier is selected from the group consisting of stearic acid, polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide, and polyethylene oxide-b-polylactide.
8. The method according to claim 1, wherein the medical device is a stent.
9. The method according to claim 1, wherein the polymer is biodegradable.
10. The method according to claim 1, wherein the bioceramic particles are nanoparticles.
11. The method according to claim 1, wherein a ratio of the weight percent of the bioceramic particles to the polymer is at least about 1:200.
12. The method according to claim 1, wherein the bioceramic particles are selected from the group consisting of calcium sulfate and hydroxyapatite.
13. A method for fabricating an implantable medical device comprising:
forming a suspension solution including a fluid, a non-reactive surface modifier, a polymer and bioceramic particles, wherein the polymer is dissolved in the fluid, and wherein the bioceramic particles are dispersed in the solution;
removing all or substantially all of the fluid to form a composite mixture, wherein the composite mixture comprises the bioceramic particles dispersed within the polymer, wherein the non-reactive surface modifier reduces the agglomeration of the bioceramic particles in the suspension solution and/or during formation of the composite mixture; and
fabricating an implantable medical device from the composite mixture.
14. The method according to claim 13, wherein the fluid is removed by evaporating the fluid.
15. The method according to claim 13, wherein the non-reactive surface modifier lowers the surface energy of the particles.
16. The method according to claim 13, further comprising mixing the suspension solution having the non-reactive surface modifier and the plurality of bioceramic particles to facilitate reducing the agglomeration.
17. The method according to claim 13, further comprising processing the composite with a shear stress higher than the fracture strength of clusters of agglomerated bioceramic particles so that agglomeration is further reduced.
18. The method according to claim 13, further comprising processing the composite with a twin-screw extruder or a kneader in such a way that agglomeration is further reduced.
19. The method according to claim 13, wherein the non-reactive surface modifier is selected from the group consisting of stearic acid, polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide, and polyethylene oxide-b-polylactide.
20. The method according to claim 13, wherein the medical device is a stent.
21. The method according to claim 13, wherein the polymer is biodegradable.
22. The method according to claim 13, wherein the bioceramic particles are nanoparticles.
23. The method according to claim 13, wherein a ratio of the weight percent of the bioceramic particles to the polymer is at least about 1:200.
24. A stent comprising:
a structural element including a bioceramic/polymer composite, the composite having a plurality of bioceramic particles dispersed within a polymer, a non-reactive surface modifier being on a surface of at least some of the particles, wherein the surface modifier reduces agglomeration of the bioceramic particles prior to and during the formation of the composite.
25. The device according to claim 24, wherein the non-reactive surface modifier is selected from the group consisting of stearic acid, polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide, and polyethylene oxide-b-polylactide.
26. The device according to claim 24, wherein the medical device is a stent.
27. The device according to claim 24, wherein the polymer is biodegradable.
28. The device according to claim 24, wherein the bioceramic particles are nanoparticles.
29. The device according to claim 24, wherein a ratio of the weight percent of the bioceramic particles to the polymer is at least about 1:200.
30. A method of fabricating an implantable medical device comprising:
processing a mixture of a polymer and agglomerated bioceramic particles to form a composite of the bioceramic particles dispersed within the polymer, wherein the processing subjects the plurality of bioceramic particles to a shear stress higher than a fracture strength of clusters of the agglomerated bioceramic particles so that agglomeration is reduced; and
fabricating an implantable medical device from the composite.
31. The method according to claim 30, wherein the polymer and the agglomerated bioceramic particles are processed with a twin-screw extruder or a kneader.
32. The method according to claim 30, wherein the medical device is a stent.
33. The method according to claim 30, wherein the polymer is biodegradable.
34. The method according to claim 30, wherein the bioceramic particles are nanoparticles.
35. The method according to claim 30, wherein a ratio of the weight percent of the bioceramic particles to the polymer is at least about 1:200.
36. The method according to claim 30, wherein the bioceramic particles are selected from the group consisting of calcium sulfate and hydroxyapatite.
37. A method of fabricating an implantable medical device comprising:
processing a mixture of a polymer and bioceramic particles to form a composite, wherein the bioceramic particles have been treated with a non-reactive surface modifier that reduces the fracture strength of clusters of the bioceramic particles, the composite comprising the bioceramic particles dispersed within the polymer; and
fabricating an implantable medical device from the composite.
38. The method according to claim 37, wherein the non-reactive surface modifier lowers the surface energy of the particles.
39. The method according to claim 37, wherein the agglomerated bioceramic particles are treated by dispersing the bioceramic particles in a solution including the non-reactive surface modifier.
40. The method according to claim 37, wherein the processing subjects the composite to a shear stress higher than fracture strength of clusters of untreated bioceramic particles so that the agglomeration is reduced.
41. The method according to claim 37, wherein the processing subjects the composite to a shear stress higher than the fracture strength of clusters of the treated bioceramic particles so that the agglomeration is reduced.
42. The method according to claim 37, wherein the composite is processed in a kneader or a twin screw extruder.
43. The method according to claim 37, wherein the non-reactive surface modifier is selected from the group consisting of stearic acid, polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide (PEO-b-PPO-b-PEO), and polyethylene oxide-b-polylactide.
44. The method according to claim 37, wherein the medical device is a stent.
45. The method according to claim 37, wherein the polymer is biodegradable.
46. The method according to claim 37, wherein the bioceramic particles are nanoparticles.
47. The method according to claim 43, wherein the bioceramic particles are selected from the group consisting of calcium sulfate and hydroxyapatite.
Description
    CROSS-REFERENCE
  • [0001]
    This application is a continuation-in-part of U.S. application Ser. No. 11/706,550 filed on Feb. 14, 2007, and a continuation-in-part of U.S. application Ser. No. 11/529,996 filed Sep. 29, 2006, and a continuation-in-part of U.S. application Ser. No. 11/523,866 filed on Sep. 19, 2006, which is a continuation-in-part of U.S. application Ser. No. 11/443,870 filed on May 30, 2006, which are all incorporated herein by reference.
  • BACKGROUND OF THE INVENTION
  • [0002]
    1. Field of the Invention
  • [0003]
    This invention relates to implantable medical devices and methods of fabricating implantable medical devices.
  • [0004]
    2. Description of the State of the Art
  • [0005]
    This invention relates to radially expandable endoprostheses, which are adapted to be implanted in a bodily lumen. An “endoprosthesis” corresponds to an artificial device that is placed inside the body. A “lumen” refers to a cavity of a tubular organ such as a blood vessel.
  • [0006]
    A stent is an example of such an endoprosthesis. Stents are generally cylindrically shaped devices, which function to hold open and sometimes expand a segment of a blood vessel or other anatomical lumen such as urinary tracts and bile ducts. Stents are often used in the treatment of atherosclerotic stenosis in blood vessels. “Stenosis” refers to a narrowing or constriction of the diameter of a bodily passage or orifice. In such treatments, stents reinforce body vessels and prevent restenosis following angioplasty in the vascular system. “Restenosis” refers to the reoccurrence of stenosis in a blood vessel or heart valve after it has been treated (as by balloon angioplasty, stenting, or valvuloplasty) with apparent success.
  • [0007]
    The treatment of a diseased site or lesion with a stent involves both delivery and deployment of the stent. “Delivery” refers to introducing and transporting the stent through a bodily lumen to a region, such as a lesion, in a vessel that requires treatment. “Deployment” corresponds to the expanding of the stent within the lumen at the treatment region. Delivery and deployment of a stent are accomplished by positioning the stent about one end of a catheter, inserting the end of the catheter through the skin into a bodily lumen, advancing the catheter in the bodily lumen to a desired treatment location, expanding the stent at the treatment location, and removing the catheter from the lumen.
  • [0008]
    In the case of a balloon expandable stent, the stent is mounted about a balloon disposed on the catheter. Mounting the stent typically involves compressing or crimping the stent onto the balloon. The stent is then expanded by inflating the balloon. The balloon may then be deflated and the catheter withdrawn. In the case of a self-expanding stent, the stent may be secured to the catheter via a constraining member such as a retractable sheath or a sock. When the stent is in a desired bodily location, the sheath may be withdrawn which allows the stent to self-expand.
  • [0009]
    The stent must be able to satisfy a number of mechanical requirements. First, the stent must be capable of withstanding the structural loads, namely radial compressive forces, imposed on the stent as it supports the walls of a vessel. Therefore, a stent must possess adequate radial strength. Radial strength, which is the ability of a stent to resist radial compressive forces, is due to strength and rigidity around a circumferential direction of the stent. Radial strength and rigidity, therefore, may also be described as, hoop or circumferential strength and rigidity.
  • [0010]
    Once expanded, the stent must adequately maintain its size and shape throughout its service life despite the various forces that may come to bear on it, including the cyclic loading induced by the beating heart. For example, a radially directed force may tend to cause a stent to recoil inward. Generally, it is desirable to minimize recoil. In addition, the stent must possess sufficient flexibility to allow for crimping, expansion, and cyclic loading. Longitudinal flexibility is important to allow the stent to be maneuvered through a tortuous vascular path and to enable it to conform to a deployment site that may not be linear or may be subject to flexure. Finally, the stent must be biocompatible so as not to trigger any adverse vascular responses.
  • [0011]
    The structure of a stent is typically composed of scaffolding that includes a pattern or network of interconnecting structural elements often referred to in the art as struts or bar arms. The scaffolding can be formed from wires, tubes, or sheets of material rolled into a cylindrical shape. The scaffolding is designed so that the stent can be radially compressed (to allow crimping) and radially expanded (to allow deployment). A conventional stent is allowed to expand and contract through movement of individual structural elements of a pattern with respect to each other.
  • [0012]
    Additionally, a medicated stent may be fabricated by coating the surface of either a metallic or polymeric scaffolding with a polymeric carrier that includes an active or bioactive agent or drug. Polymeric scaffolding may also serve as a carrier of an active agent or drug.
  • [0013]
    Furthermore, it may be desirable for a stent to be biodegradable. In many treatment applications, the presence of a stent in a body may be necessary for a limited period of time until its intended function of, for example, maintaining vascular patency and/or drug delivery is accomplished. Therefore, stents fabricated from biodegradable, bioabsorbable, and/or bioerodable materials such as bioabsorbable polymers should be configured to completely erode only after the clinical need for them has ended.
  • [0014]
    A potential problem with polymeric stents is that their struts or bar arms can crack during crimping and expansion. This is especially the case with brittle polymers. The localized portions of the stent pattern subjected to substantial deformation during crimping and expansion tend to be the most vulnerable to failure.
  • [0015]
    Therefore, it is desirable for a stent to have flexibility and resistance to cracking during deployment. It is also advantageous for a stent to be rigid and resistant to creep after deployment. It would also be desirable to be able to control the degradation rate of the device.
  • SUMMARY OF THE INVENTION
  • [0016]
    Certain embodiments of the present invention include a method of fabricating an implantable medical device comprising: treating the surface of a plurality of bioceramic particles with a non-reactive surface modifier; forming a composite including the treated bioceramic particles dispersed within a polymer, the non-reactive surface modifier reducing the agglomeration of the treated bioceramic particles during the formation; and fabricating an implantable medical device from the composite.
  • [0017]
    Further embodiments of the present invention include a method for fabricating an implantable medical device comprising: forming a suspension solution including a fluid, a non-reactive surface modifier, a polymer and bioceramic particles, wherein the polymer is dissolved in the fluid, and wherein the bioceramic particles are dispersed in the solution; removing all or substantially all of the fluid to form a composite mixture, wherein the composite mixture comprises the bioceramic particles dispersed within the polymer, wherein the non-reactive surface modifier reduces the agglomeration of the bioceramic particles in the suspension solution and during formation of the composite mixture; and fabricating an implantable medical device from the composite mixture.
  • [0018]
    Additional embodiments of the present invention include a stent comprising: a structural element including a bioceramic/polymer composite, the composite having plurality of bioceramic particles dispersed within a polymer, a non-reactive surface modifier being on a surface of at least some of the particles, wherein the surface modifier reduces agglomeration of the bioceramic particles during the formation of the composite.
  • [0019]
    Certain other embodiments of the present invention include a method of fabricating an implantable medical device comprising: subjecting a mixture of bioceramic particles and polymer to high sheer stress using twin-screw extruder or a batch mixer; forming a composite including the bioceramic particles dispersed within a polymer, the mechanical smash, reducing the agglomeration of the bioceramic particles during the formation; and fabricating an implantable medical device from the composite.
  • [0020]
    Some embodiments of the present invention include a method of fabricating an implantable medical device comprising: treating the surface of a plurality of bioceramic particles with a non-reactive surface modifier; subjecting a mixture of the treated bioceramic particles and polymer to high sheer stress using twin-screw extruder or a batch mixer; forming a composite including the treated bioceramic particles dispersed within a polymer, the non-reactive surface modifier or mechanical smash reducing the agglomeration of the treated bioceramic particles during the formation; and fabricating an implantable medical device from the composite.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0021]
    FIG. 1 depicts a three-dimensional view of a stent.
  • [0022]
    FIG. 2A depicts a section of a structural element from the stent depicted in FIG. 1.
  • [0023]
    FIG. 2B depicts bioceramic particles dispersed within a polymer matrix.
  • [0024]
    FIG. 3 depicts a schematic plot of the crystal nucleation rate, the crystal growth rate, and the overall rate of crystallization for a semicrystalline polymer.
  • [0025]
    FIG. 4 is a graph depicting the peak stress for PLLA and PLLA/HAP composites.
  • [0026]
    FIG. 5 is a graph depicting the break strain for PLLA and PLLA/HAP composites.
  • [0027]
    FIG. 6 is a graph depicting Young's modulus for PLLA and PLLA/HAP composite stent in compression testing.
  • [0028]
    FIG. 7 is a graph depicting the radial stress for PLGA and PLGA/HAP composite stent in compression testing.
  • [0029]
    FIG. 8 is a graph depicting the compression modulus for PLGA and PLGA/HAP composite stent in compression testing.
  • [0030]
    FIG. 9 is a graph depicting recoil testing of PLGA and PLGA/HAP composite stent.
  • [0031]
    FIGS. 10A-D depict photographic images of a PLGA/calcium sulfate composite stent with a weight ratio of PLGA/calcium sulfate of 100:1 at zero time point.
  • [0032]
    FIGS. 11A-D depict photographic images of a PLGA/calcium sulfate composite stent with a weight ratio of PLGA/calcium sulfate of 100:1 at 16 hours of accelerated aging.
  • [0033]
    FIG. 12A depicts a SEM photographic image of LPLG/unmodified calcium sulfate composite before surface modification
  • [0034]
    FIG. 12B depicts a SEM photographic image of LPLG/PEO-b-PPO-b-PEO modified calcium sulfate composite after surface modification
  • [0035]
    FIG. 12C depicts a SEM photographic image of LPLG/stearic acid modified calcium sulfate composite after surface modification
  • [0036]
    FIG. 13A depicts a photographic image of LPLG/calcium sulfate composite formed using twin screw extruder
  • [0037]
    FIG. 13B depicts a photographic image of LPLG/calcium sulfate composite formed using single screw extruder
  • [0038]
    FIG. 13C depicts a photographic image of LPLG/PEO-b-PPO-b-PEO modified calcium sulfate composite formed using twin screw extruder
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0039]
    Those of ordinary skill in the art will realize that the following description of the invention is illustrative only and not in any way limiting. Other embodiments of the invention will readily suggest themselves to such skilled persons based on the disclosure herein. All such embodiments are within the scope of this invention.
  • [0040]
    For the purposes of the present invention, the following terms and definitions apply:
  • [0041]
    The “glass transition temperature,” Tg, is the temperature at which the amorphous domains of a polymer change from a brittle vitreous state to a solid deformable or ductile state at atmospheric pressure. In other words, the Tg corresponds to the temperature where the onset of segmental motion in the chains of the polymer occurs. When an amorphous or semicrystalline polymer is exposed to an increasing temperature, the coefficient of expansion and the heat capacity of the polymer both increase as the temperature is raised, indicating increased molecular motion. As the temperature is raised the actual molecular volume in the sample remains constant, and so a higher coefficient of expansion points to an increase in free volume associated with the system and therefore increased freedom for the molecules to move. The increasing heat capacity corresponds to an increase in heat dissipation through movement. Tg of a given polymer can be dependent on the heating rate and can be influenced by the thermal history of the polymer. Furthermore, the chemical structure of the polymer heavily influences the glass transition by affecting mobility.
  • [0042]
    “Stress” refers to force per unit area, as in the force acting through a small area within a plane. Stress can be divided into components, normal and parallel to the plane, called normal stress and shear stress, respectively. True stress denotes the stress where force and area are measured at the same time. Conventional stress, as applied to tension and compression tests, is force divided by the original gauge length.
  • [0043]
    “Strength” refers to the maximum stress along an axis which a material will withstand prior to fracture. The ultimate strength is calculated from the maximum load applied during the test divided by the original cross-sectional area.
  • [0044]
    “Modulus” may be defined as the ratio of a component of stress or force per unit area applied to a material divided by the strain along an axis of applied force that results from the applied force. For example, a material has both a tensile and a compressive modulus. A material with a relatively high modulus tends to be stiff or rigid. Conversely, a material with a relatively low modulus tends to be flexible. The modulus of a material depends on the molecular composition and structure, temperature of the material, amount of deformation, and the strain rate or rate of deformation. For example, below its Tg, a polymer tends to be brittle with a high modulus. As the temperature of a polymer is increased from below to above its Tg, its modulus decreases.
  • [0045]
    “Strain” refers to the amount of elongation or compression that occurs in a material at a given stress or load.
  • [0046]
    “Elongation” may be defined as the increase in length in a material which occurs when subjected to stress. It is typically expressed as a percentage of the original length.
  • [0047]
    “Toughness” is the amount of energy absorbed prior to fracture, or equivalently, the amount of work required to fracture a material. One measure of toughness is the area under a stress-strain curve from zero strain to the strain at fracture. Thus, a brittle material tends to have a relatively low toughness.
  • [0048]
    “Solvent” is defined as a substance capable of dissolving or dispersing one or more other substances or capable of at least partially dissolving or dispersing the substance(s) to form a uniformly dispersed solution at the molecular- or ionic-size level. The solvent should be capable of dissolving at least 0.1 mg of the polymer in 1 ml of the solvent, and more narrowly 0.5 mg in 1 ml at ambient temperature and ambient pressure.
  • [0049]
    As used herein, an “implantable medical device” includes, but is not limited to, self-expandable stents, balloon-expandable stents, stent-grafts, implantable cardiac pacemakers and defibrillators; leads and electrodes for the preceding; implantable organ stimulators such as nerve, bladder, sphincter and diaphragm stimulators, cochlear implants; prostheses, vascular grafts, grafts, artificial heart valves and cerebrospinal fluid shunts.
  • [0050]
    An implantable medical device can be designed for the localized delivery of a therapeutic agent. A medicated implantable medical device may be constructed by coating the device with a coating material containing a therapeutic agent. The substrate of the device may also contain a therapeutic agent.
  • [0051]
    FIG. 1 depicts a three-dimensional view of stent 100. In some embodiments, a stent may include a pattern or network of interconnecting structural elements 110. Stent 100 may be formed from a tube (not shown). Stent 100 includes a pattern of structural elements 110, which can take on a variety of patterns. The structural pattern of the device can be of virtually any design. The embodiments disclosed herein are not limited to stents or to the stent pattern illustrated in FIG. 1. The embodiments are easily applicable to other patterns and other devices. The variations in the structure of patterns are virtually unlimited. A stent such as stent 100 may be fabricated from a tube by forming a pattern with a technique such as laser cutting or chemical etching.
  • [0052]
    The geometry or shape of an implantable medical device may vary throughout its structure to allow radial expansion and compression. A pattern may include portions of structural elements or struts that are straight or relatively straight, an example being a portion 120. In addition, patterns may include structural elements or struts that include curved or bent portions such as portions 130, 140, and 150.
  • [0053]
    An implantable medical device can also be made partially or completely from a biodegradable, bioabsorbable, or biostable polymer. A polymer for use in fabricating an implantable medical device can be biostable, bioabsorbable, biodegradable or bioerodable. Biostable refers to polymers that are not biodegradable. The terms biodegradable, bioabsorbable, and bioerodable are used interchangeably and refer to polymers that are capable of being completely degraded and/or eroded when exposed to bodily fluids such as blood and can be gradually resorbed, absorbed, and/or eliminated by the body. The processes of breaking down and absorption of the polymer can be caused by, for example, hydrolysis and metabolic processes.
  • [0054]
    However, polymers tend to have a number of shortcomings for use as materials for implantable medical devices such as stents. Many biodegradable polymers have a relatively low modulus at the physiological conditions in the human body. In general, compared to metals, the strength to weight ratio of polymers is smaller than that of metals. A polymeric stent with inadequate radial strength can result in mechanical failure or recoil inward after implantation into a vessel. To compensate for the relatively low modulus, a polymeric stent requires significantly thicker struts than a metallic stent, which results in an undesirably large profile.
  • [0055]
    Another shortcoming of polymers is that many polymers, such as biodegradable polymers, tend to be brittle under physiological conditions or conditions within a human body. Specifically, such polymers can have a Tg above human body temperature which is approximately 37° C. These polymer systems exhibit a brittle fracture mechanism in which there is little or no plastic deformation prior to failure. As a result, a stent fabricated from such polymers can have insufficient toughness for the range of use of a stent.
  • [0056]
    Other potential problems with polymeric stents include creep, stress relaxation, and physical aging. Creep refers to the gradual deformation that occurs in a polymeric contruct subjected to an applied load. Creep occurs even when the applied load is constant.
  • [0057]
    It is believed that the delayed response of polymer chains to stress during deformation causes creep behavior. As a polymer is deformed, polymeric chains in an initial state rearrange to adopt a new equilibrium configuration. Rearrangement of chains takes place slowly with the chains retracting by folding back to their initial state. For example, an expanded stent can retract radially inward, reducing the effectiveness of a stent in maintaining desired vascular patency. The rate at which polymers creep depends not only on the load, but also on temperature. In general, a loaded construct creeps faster at higher temperatures.
  • [0058]
    Stress relaxation is also a consequence of delayed molecular motions as in creep. Contrary to creep, however, which is experienced when the load is constant, stress relaxation occurs when deformation (or strain) is constant and is manifested by a reduction in the force (stress) required to maintain a constant deformation.
  • [0059]
    Physical aging, as used herein, refers to densification in the amorphous regions of a semi-crystalline polymer. Densification is the increase in density of a material or region of a material. Densification, and thus physical aging, is also the result of relaxation or rearrangement of polymer chains.
  • [0060]
    Various embodiments of the present invention include an implantable medical device fabricated from a composite including a polymer matrix or continuous phase and bioceramic particles as a discrete phase. The bioceramic particles may tend to reduce or eliminate a number of the above-mentioned shortcomings of polymers. For example, the bioceramic particles can increase the toughness and modulus and modify the degradation rate of the polymer. In some embodiments, the composite may include a plurality of bioceramic particles dispersed within the polymer.
  • [0061]
    In general, it is desirable for the bioceramic particles to be uniformly dispersed throughout the biodegradable polymer. The more uniform the dispersion of the particles results in more uniform properties of the composite and a device fabricated from the composite. For example, a uniform dispersion can result in a uniform increase in toughness and modulus and modification of degradation rate. In some embodiments, the bioceramic particles are uniformly or substantially uniformly dispersed within the biodegradable polymer.
  • [0062]
    In certain embodiments, a structural element of an implantable medical device may be fabricated from a bioceramic/polymer composite. Structural elements can include, but are not limited to, any supporting element such as a strut, wire, or filament. FIG. 2A depicts a section 200 of a structural element 110 from stent 100. A portion 210 of section 200 is shown in an expanded view in FIG. 2B. FIG. 2B depicts bioceramic particles 220 dispersed throughout a polymer matrix 230.
  • [0063]
    Bioceramics can include any ceramic material that is compatible with the human body. More generally, bioceramic materials can include any type of compatible inorganic material or inorganic/organic hybrid material. Bioceramic materials can include, but are not limited to, alumina, zirconia, apatites, calcium phosphates, silica based glasses, or glass ceramics, and pyrolytic carbons. Bioceramic materials can be bioabsorbable and/or active. A bioceramic is active if it actively takes part in physiological processes. A bioceramic material can also be “inert,” meaning that the material does not absorb or degrade under physiological conditions of the human body and does not actively take part in physiological processes.
  • [0064]
    Illustrative examples of apatites and other calcium phosphates, include, but are not limited hydroxyapatite (Ca10(PO4)6(OH)2), floroapatite (Ca10(PO4)6F2), carbonate apatide (Ca10(PO4)6CO3), tricalcium phosphate (Ca3(PO4)2), octacalcium phosphate (Ca8H2(PO4)6-5H2O), octacalcium phosphate (Ca8H2(PO4)6-5H2O), calcium pyrophosphate (Ca2P2O7-2H2O), tetracalcium phosphate (Ca4P2O9), and dicalcium phosphate dehydrate (CaHPO4-2H2O).
  • [0065]
    The term bioceramics can also include bioactive glasses that are bioactive glass ceramics composed of compounds such as SiO2, Na2O, CaO, and P2O5. For example, a commercially available bioactive glass, Bioglass®, is derived from certain compositions of SiO2—Na2O—K2O—CaO—MgO—P2O5 systems. Some commercially available bioactive glasses include, but are not limited to:
  • [0066]
    45S5: 46.1 mol % SiO2, 26.9 mol % CaO, 24.4 mol % Na2O and 2.5 mol % P2O5;
  • [0067]
    58S: 60 mol % SiO2, 36 mol % CaO, and 4 mol % P2O5; and
  • [0068]
    S70C30: 70 mol % SiO2, 30 mol % CaO.
  • [0069]
    Another commercially available glass ceramic is A/W.
  • [0070]
    In some embodiments, bioceramic particles in a composite implantable medical device, may be used to inhibit or prevent infection since some bioceramics can have an anti-infective property. Bioceramics may release various ions such as calcium and phosphate ions which broadly exist in human body fluid and blood plasma. Examples of bioceramics that release calcium and/or phosphate ions include various calcium phosphates and bioactive glasses. The released ions may depress foreign body reaction. Trends Biomater. Artif. Tren, Vol 18 (1), pp 9-17.
  • [0071]
    As indicated above, an implantable medical device such as a stent can be medicated by incorporating an active agent in a coating over the device or within the substrate of the device. In some embodiments, the ions released from bioceramics can have an additive therapeutic and/or a synergistic therapeutic effect to the active agent. For example, ions can be used in conjunction with anti-proliferative and/or anti-inflammatory agents.
  • [0072]
    Bioceramic particles can be partially or completely made from a biodegradable, bioabsorbable, or biostable ceramic. Examples of bioabsorbable bioceramics include various types of bioglass materials, tetracalcium phosphate, amorphous calcium phosphate, alpha-tricalcium phosphate, and beta-tricalcium phosphate. Biostable bioceramics include alumina and zirconia.
  • [0073]
    Various sizes of the bioceramic particles may be used in the composite. For example, the bioceramic particles can include, but are not limited to, nanoparticles and/or micro particles. A nanoparticle refers to a particle with a characteristic length (e.g., diameter) in the range of about 1 nm to about 1,000 nm. A micro particle refers to a particle with a characteristic length in the range of greater than 1,000 nm and less than about 10 micrometers. Additionally, bioceramic particles can be of various shapes, including but not limited to, spheres and fibers.
  • [0074]
    Additionally, the particles size distribution can be important in modifying the properties of the polymer. Generally, a narrow size distribution is preferable.
  • [0075]
    The composite of a structural element of a device may have between 0.01% and 10% of bioceramic particles by weight, or more narrowly, between 0.5% and 2% bioceramic particles by weight as compared to the polymer matrix of the composite.
  • [0076]
    As indicated above, the bioceramic particles can reduce or eliminate a number of shortcomings of polymers that are used for implantable medical devices. In one aspect of the invention, bioceramic particles can increase the fracture toughness of polymers of implantable medical device. In general, the higher the fracture toughness, the more resistant a material is to the propagation of cracks. In some embodiments, bioceramic particles may be used in a composite having a matrix polymer that is brittle at physiological conditions. In particular, such a polymer can have a Tg above body temperature. In one embodiment, the bioceramic particles may be nanoparticles.
  • [0077]
    Certain regions of an implantable medical device, such as a stent, experience a high degree of stress and strain when the device is under stress during use. For example, when a stent is crimped and deployed, curved or bending regions such as portions 130, 140, and 150 can have highly concentrated strain which can lead to fracture. The bioceramic particles can increase fracture toughness by reducing the concentration of strain by dispersing the strain over a large volume of the material. Particles can absorb energy due to applied stress and disperse energy about a larger volume in the bioceramic/polymer composite.
  • [0078]
    Therefore, rather than being highly concentrated the stress and strain in a device fabricated from a bioceramic composite is divided into many small interactions involving numerous individual particles. When a crack is initiated in the material and starts traveling through the composite, the crack breaks up into finer and finer cracks due to interaction with the particles. Thus, the particles tend to dissipate the energy of imparted to the device by the applied stress. For a give weight ratio of particles to matrix, as the size of the particles decreases the number of particles dispersed throughout the device per unit volume also increases. Thus, the number of particles to disperse the energy of applied stress to the device increases. Therefore, it is advantageous to use nanoparticles to increase the toughness of the polymer. It has been shown that the fracture toughness of a polymeric material can be improved by using nanoparticles as a discrete or reinforcing phase in a composite. J. of Applied Polymer Science, 94 (2004) 796-802.
  • [0079]
    Bioceramic particles, more particularly nano-bioceramic particles, by providing more crystallites in a network in the bioceramic/polymer composite increase fracture toughness. In yet another aspect of the invention, bioceramic particles can be used to increase the the strength and modulus of the polymer. As indicated above, a polymeric stent requires a high radial strength in order to provide effective scaffolding of a vessel. Many biodegradable polymers have a relatively low strength and modulus as compared to metals. A composite with bioceramic particles with a higher modulus than a matrix polymer may have a higher strength and modulus than the polymer. The higher strength and modulus may allow for the manufacture of a composite stent with much thinner struts than a stent fabricated from the matrix polymer alone. Examples of relatively low modulus polymers include, but are not limited to, poly(D,L-lactide-co-glycolide), poly(lactide-co-caprolactone), poly(lactide-co-trimethylene carbonate), poly(glycolide-co-caprolactone), and poly(D,L-lactide). It has been reported that composites with nanoparticles can increase the modulus of a polymer by 1-2 orders of magnitude. Mechanical Properties of Polymers and Composites, Lawrence E. Nielsen and Robert F. Landel, 2nd ed., p. 384-385 (1993).
  • [0080]
    In addition, bioceramic particles in a polymer composite can also reduce or eliminate creep, stress relaxation, and physical aging. It is believed that particles can act as “net point” that reduce or inhibit movement of polymer chains in amorphous regions of a polymer.
  • [0081]
    Additionally, in composites fabricated from semicrystalline polymers, the crystallinity of a bioceramic/polymer composite that forms an implantable device can be controlled to reduce or eliminate creep, stress relaxation, and physical aging. As indicated above, these phenomena in a polymer are due to rearrangement or relaxation of polymer chains.
  • [0082]
    In general, as the crystallinity of a semicrystalline polymer increases, physical aging creep, and stress relaxation are reduced. This is likely due to the fact that polymer chains in the amorphous domains capable of movement are reduced by the crystalline domains. However, increasing crystallinity can result in brittleness in a polymer at physiological conditions.
  • [0083]
    In further embodiments, a structural element of an implantable medical device may include a composite having a plurality of crystalline domains dispersed within an amorphous biodegradable polymeric matrix phase. The crystalline domains may be formed around bioceramic particles. In certain embodiments, the composite that makes up the structural element may have a relatively low crystallinity. For example, the crystallinity can be less than 50%, 30%, 20%, or less than 10%.
  • [0084]
    Additionally, the device can be fabricated so that the resulting composite has a relatively large number of crystalline domains that are relatively small. In certain embodiments, the average crystal size can be less than 10 microns, or less than 5 microns. As the size of the crystalline domains decreases along with an increase in the number of domains, the polymer may become less brittle and, which increases the fracture toughness. Although the crystallinity of the resulting polymer can be relatively low, the presence of the relatively large number of relatively small crystalline domains can reduce or eliminate physical aging, creep, and stress relaxation.
  • [0085]
    The size and number of crystallites domains can be controlled during formation of a polymer construct from an implantable medical device is fabricated. Polymer constructs, such as tubes, can be formed using various types of forming methods, including, but not limited to extrusion or injection molding. Representative examples of extruders include, but are not limited to, single screw extruders, intermeshing co-rotating and counter-rotating twin-screw extruders, and other multiple screw masticating extruders.
  • [0086]
    In some embodiments, a mixture of a polymer and bioceramic particles can be extruded to form a polymer construct, such as a tube. A polymer melt mixed with the bioceramic particles can be conveyed through an extruder and forced through a die in the shape of as an annular film in the shape of a tube. The annular film can be cooled below the melting point, Tm, of the polymer to form an extruded polymeric tube. For example, the annular film may be conveyed through a water bath at a selected temperature. Alternatively, the annular film may be cooled by a gas at a selected temperature. The annular film may be cooled at or near an ambient temperature, e.g. 25° C. Alternatively, the annular film may be cooled at a temperature below ambient temperature.
  • [0087]
    In general, crystallization in a polymer tends to occur in a polymer at temperatures between Tg and Tm of the polymer. Therefore, in some embodiments, the temperature of the polymer construct during cooling can be between Tg and Tm. As the temperature of the extruded mixture is cooled below Tm to form a polymer construct, such as a tube, the bioceramic particles provide a point of nucleation in the polymer melt for the formation of crystalline domains.
  • [0088]
    A network of many small crystalline domains is formed, which can work to tie crystalline domains together and reduce, inhibit or prevent fracturing, creep, stress relaxation, and physical aging of the polymer. The crystalline domains can serve as net points in the amorphous domains that restrict the freedom of movement of polymer chains in the amorphous domain. As a result, physical aging, creep, and stress relaxation can be reduced. In addition, for the reasons discussed above, the toughness of the polymer is also increased.
  • [0089]
    In general, both microparticles and nanoparticles can be used as nucleation points. However, as the number of particles increases and size of the particles decreases, the crystalline domains become more effective in increasing fracture toughness and reducing physical aging, creep, and stress relaxation. The closer the crystalline domains are to one another within the amorphous domain of a polymer, the more the crystalline domains can limit the degree of freedom movement of polymer chains in the amorphous domain. Therefore, nanoparticles may be more effective in reducing physical aging, creep, and stress relaxation.
  • [0090]
    In certain embodiments, the size of the crystalline domains can be controlled by the temperature of the cooling polymer construct from an extruder. In general, crystallization tends to occur in a polymer at temperatures between Tg and Tm of the polymer. The rate of crystallization in this range varies with temperature. FIG. 3 depicts a schematic plot of the crystal nucleation rate (RN), the crystal growth rate (RCG), and the overall rate of crystallization (RCO). The crystal nucleation rate is the growth rate of new crystals and the crystal growth rate is the rate of growth of formed crystals. The overall rate of crystallization is the sum of curves RN and RCG.
  • [0091]
    In certain embodiments, the temperature of the cooling polymer construct can be at a temperature at which the overall crystallization rate is relatively low. At such a temperature, the increase in crystallinity is predominantly due to formation of crystalline domains around the bioceramic particles, rather than the growth of existing crystals. In some embodiments, the temperature can be in a range in which the crystal nucleation rate is larger than the crystal growth rate. In one embodiment, the temperature can be in a range in which the crystal nucleation rate is substantially larger than the crystal growth rate. For example, the temperature can be where the ratio of the crystal nucleation rate to crystal growth rate is 2, 5, 10, 50, 100, or greater than 100. In another embodiment, the temperature range may be in range, ΔT, shown in FIG. 3, between about Tg to about 0.25(Tm−Tg)+Tg.
  • [0092]
    In general, good bonding between a continuous phase and a discrete or reinforcing phase in a composite material facilitates improvement of the mechanical performance of the composite. For example, increase of the modulus and fracture toughness of a polymer due to a bioceramic particle phase can be enhanced by good bonding between the polymer and particles.
  • [0093]
    In some embodiments, bioceramic particles may include an adhesion promoter to improve the adhesion between the particles and the polymer matrix. In one embodiment, an adhesion promoter can include a coupling agent. A coupling agent refers to a chemical substance capable of reacting with both the bioceramic particle and the polymer matrix of the composite material. A coupling agent acts as an interface between the polymer and the bioceramic particle to form a chemical bridge between the two to enhance adhesion.
  • [0094]
    The adhesion promoter may include, but is not limited to, silane and non-silane coupling agents. For example, the adhesion promoter may include 3-aminopropyltrimethoxysilane, 3-aminopropyltriethoxysilane, aminopropylmethyldiethoxy silane, organotrialkoxysilanes, titanates, zirconates, and organic acid-chromium chloride coordination complexes. In particular, 3-aminopropyltrimethoxysilane has been shown to facilitate adhesion between poly(L-lactide) and bioglass. Biomaterials 25 (2004) 2489-2500.
  • [0095]
    In some embodiments, the surface of the bioceramic particles may be treated with an adhesion promoter prior to mixing with the polymer matrix. In one embodiment, the bioceramic particles can be treated with a solution containing the adhesion promoter. Treating can include, but is not limited to, coating, dipping, or spraying the particles with an adhesion promoter or a solution including the adhesion promoter. The particles can also be treated with a gas containing the adhesion promoter. In one embodiment, treatment of the bioceramic particles includes mixing the adhesion promoter with solution of distilled water and a solvent such as ethanol and then adding bioceramic particles. The bioceramic particles can then be separated from the solution, for example, by a centrifuge, and the particles can be dried. The bioceramic particles may then used to form a polymer composite. In an alternative embodiment, the adhesion promoter can be added to the particles during formation of the composite. For example, the adhesion promoter can be mixed with a bioceramic/polymer mixture during extrusion.
  • [0096]
    As indicated above, a device may be composed in whole or in part of materials that degrade, erode, or disintegrate through exposure to physiological conditions within the body until the treatment regimen is completed. The device may be configured to disintegrate and disappear from the region of implantation once treatment is completed. The device may disintegrate by one or more mechanisms including, but not limited to, dissolution and chemical breakdown.
  • [0097]
    The duration of a treatment period depends on the bodily disorder that is being treated. For illustrative purposes only, in treatment of coronary heart disease involving use of stents in diseased vessels, the duration can be in a range from about a month to a few years. However, the duration is typically in a range from about six to twelve months. Thus, it is desirable for an implantable medical device, such as a stent, to have a degradation time at or near the duration of treatment. Degradation time refers to the time for an implantable medical device to substantially or completely erode away from an implant site.
  • [0098]
    Several mechanisms may be relied upon for erosion and disintegration of implantable devices which include, but are not limited to, mechanical, chemical breakdown and dissolution. Therefore, bodily conditions can include, but are not limited to, all conditions associated with bodily fluids (contact with fluids, flow of fluids) and mechanical forces arising from body tissue in direct and indirect contact with a device. Degradation of polymeric materials principally involves chemical breakdown involving enzymatic and/or hydrolytic cleavage of device material due to exposure to bodily fluids such as blood.
  • [0099]
    Chemical breakdown of biodegradable polymers results in changes of physical and chemical properties of the polymer, for example, following exposure to bodily fluids in a vascular environment. Chemical breakdown may be caused by, for example, hydrolysis and/or metabolic processes. Hydrolysis is a chemical process in which a molecule is cleaved into two parts by the addition of a molecule of water. Consequently, the degree of degradation in the bulk of a polymer is strongly dependent on the diffusivity, and hence the diffusion rate of water in the polymer.
  • [0100]
    Another deficiency of some biodegradable polymers, such as poly(L-lactide), is that the degradation rate is slow and results in a degradation time of a stent outside of the desired range. A preferred degradation is from six to twelve months. Increasing the equilibrium content of moisture in a biodegradable polymer that degrades by hydrolysis can increase the degradation rate of a polymer. Various embodiments of the present invention include increasing the equilibrium moisture content in a polymer of a device to accelerate the degradation rate.
  • [0101]
    In some embodiments, bioabsorbable bioceramic particles may be included in a bioceramic/polymer composite device to increase the degradation rate of the polymer and to decrease the degradation time of a device made from the composite. In an embodiment, the degradation rate of a bioceramic/polymer composite device can be tuned and/or adjusted to a desired time frame. As the bioceramic particle erodes within the polymeric matrix, the porosity of the matrix increases. The increased porosity increases the diffusion rate of moisture through the polymeric matrix, and thus, the equilibrium moisture content of the polymeric matrix. As a result, the degradation rate of the polymer is increased. The porous structure also increases the transport of degradation products out of the matrix, which also increases the degradation rate of the matrix.
  • [0102]
    In certain embodiments, the degradation rate and degradation time of the device can be tuned or controlled through variables such as the type of bioceramic material and the size and shape of particles. In some embodiments, bioceramic materials can be selected to have a higher degradation rate than the polymer matrix. The faster the degradation rate of the bioceramic material, the faster the porosity of the polymer matrix increases which results in a greater increase in the degradation rate of the polymer matrix. Additionally, the size of the particles influence the time for erosion of the particles. The smaller the particles, the faster the erosion of the particles because of the higher surface area per unit mass of particles.
  • [0103]
    For example, nanoparticles may have a relatively fast erosion rate compared to microparticles. Additionally, elongated particles, such as fibers, may tend to erode faster on a per unit mass basis due to the higher surface area per unit mass of the particle. Also, short fibers may tend to erode faster than longer fibers. Short fibers refer to long fibers than have been cut into short lengths. In some embodiments, the short fibers may be made by forming fibers as described above, and cutting them into short lengths. In one embodiment, a length of at least a portion of the short fibers is substantially smaller than a diameter of the formed tube. For example, in some embodiments, the short fibers may be less than 0.05 mm long. In other embodiments, the short fibers may be between 0.05 and 8 mm long, or more narrowly between 0.1 and 0.4 mm long or 0.3 and 0.4 mm long.
  • [0104]
    Furthermore, the size and distribution of pores created by erosion of bioceramic particles can also influence the degradation rate and time of the polymer matrix. Smaller particles, such as nanoparticles, create a porous network that exposes a larger volume of polymer matrix to bodily fluid than larger particles, like microparticles. As a result the degradation rate and time of the matrix may be higher when nanoparticles are used rather than microparticles.
  • [0105]
    Through appropriate selection of the type of material for the particles and the size and shape of the particles, the particles and the device can be designed to have a selected erosion rates and degradation time. For example, the particles can designed erode away in several minutes, hours, days, or a month upon exposure to bodily fluid.
  • [0106]
    As indicated above, many biodegradable polymers degrade by the mechanism of hydrolysis. The rate of the hydrolysis reaction tends to increase as the pH decreases. Since the degradation products of such polymers as polylactides are acidic, the degradation products have an autocatalytic effect. Therefore, the pH of the degradation products of the bioceramics can also affect the degradation rate of a device. Therefore, bioceramic particles with acidic degradation by-products may further increase the rate of degradation of a matrix polymer.
  • [0107]
    For example, tricalcium phosphate releases acidic degradation products. Thus, some embodiments may include a composite including a bioceramic having acidic degradation products upon exposure to bodily fluids. The acidic degradation products can increase the degradation rate of the polymer which can decrease the degradation time of the device.
  • [0108]
    In other embodiments, a composite can have bioceramic particles that have basic degradation products. For example, hydroxyapatite releases basic degradation products. The basic degradation products of the bioceramic particles can reduce the autocatalytic effect of the polymer degradation by neutralizing the acidic degradation products of the polymer degradation. In some embodiments, the basic degradation products of the bioceramic particles can reduce the degradation rate of the polymer. Additionally, bioceramic particles having a basic degradation product may also depress foreign body reaction.
  • [0109]
    For example, in rapidly eroding implantable medical devices, such as, for example poly(lactide-co-glycolide) which can potentially produce a local pH drop due to the rapid release of acidic degradation products, the use of bioceramic particles having a basic degradation product may buffer the reaction and neutralize the local pH drop.
  • [0110]
    Furthermore, some semi-crystalline biodegradable polymers have a degradation rate that is slower than desired for certain stent treatments. As a result, the degradation time of a stent made from such polymers can be longer than desired. For example, a stent made from poly(L-lactide) can have a degradation time of between about two and three years. In some treatment situations, a degradation time of less than a year may be desirable, for example, between four and eight months.
  • [0111]
    As discussed above, the degradation of a hydrolytically degradable polymer follows a sequence including water penetration into the polymer followed by hydrolysis of bonds in the polymer. Thus, the degradation of a polymer can be influenced by its affinity for water and the diffusion rate of water through the polymer. A hydrophobic polymer has a low affinity for water which results in a relatively low water penetration. In addition, the diffusion rate of water through crystalline regions of a polymer is lower than amorphous regions. Thus, as either the affinity of a polymer for water decreases or the crystallinity increases, water penetration and water content of a polymer decreases.
  • [0112]
    Further embodiments of a biodegradable implantable medical device may be fabricated from a copolymer. In certain embodiments, the copolymer can be a matrix in a bioceramic/polymer composite. The copolymer can include hydrolytically degradable monomers or functional groups that provide desired degradation characteristics. For instance, the copolymer can include functional groups that increase water penetration and water content of the copolymer. In some embodiments, a copolymer can include a primary functional group and at least one additional secondary functional group. In one embodiment, the copolymer may be a random copolymer including the primary functional group and at least one additional secondary functional group.
  • [0113]
    In an embodiment, the copolymer with at least one secondary functional group can have a higher degradation rate than a homopolymer composed of the primary functional group. A stent fabricated from the copolymer can have a lower degradation time than a stent fabricated from a homopolymer composed of the primary functional group.
  • [0114]
    In an embodiment, the weight percent of the secondary functional group can be selected or adjusted to obtain a desired degradation rate of the copolymer or degradation time of a stent made from the copolymer. In some exemplary embodiments, the weight percent of the secondary functional group in a copolymer can be at least 1%, 5%, 10%, 15%, 30%, 40%, or, at least 50%. In certain exemplary embodiments, a secondary functional group can be selected and the weight percent of the a secondary functional group can be adjusted so that the degradation time of a stent, with or without dispersed bioceramic particles, can be less than 18 months, 12 months, 8 months, 5 months, or more narrowly, less than 3 month.
  • [0115]
    In some embodiments, the copolymer with at least one secondary functional group can have a lower crystallinity than a homopolymer composed of the primary functional group. It is believed that inclusion of a secondary functional group can perturb the crystalline structure of a polymer including the primary functional group, resulting in a reduced crystallinity. As a result, a stent fabricated from the copolymer has a larger percentage of amorphous regions, which allow greater water penetration. Thus, the degradation rate of the copolymer can be increased and the degradation time of a stent made from the copolymer can be decreased.
  • [0116]
    In one embodiment, a secondary functional group can be a stereoisomer of the primary functional group. One exemplary embodiment can include a poly(L-lactide-co-DL-lactide) copolymer. DL-lactide can be a secondary functional group that perturbs the crystalline structure of the poly(L-lactide) so that the copolymer has a lower crystallinity than the poly(L-lactide).
  • [0117]
    In some embodiments, increasing the number of secondary functional groups in the copolymer can result in a decrease in modulus of the copolymer as compared to a homopolymer of the primary functional group. The decrease in modulus can be due to the decrease in crystallinity. The decrease in modulus can reduce the ability of a stent to support a vessel. Thus, the weight percent of the secondary functional group can be adjusted so that the ability of a stent to act as structural support is not substantially reduced. The inclusion of bioceramic particles in the copolymer can partially or completely compensate for the reduction in the modulus of the copolymer.
  • [0118]
    In other embodiments, the copolymer can include at least one secondary functional group with a greater affinity for water than the primary functional group. The secondary functional group can be less hydrophobic or more hydrophilic than the primary functional group. The decreased hydrophobicity or increased hydrophilicity can increase the concentration of water near bonds prone to hydrolysis, increasing the degradation rate and lowering the degradation time of a stent made from the copolymer.
  • [0119]
    In certain embodiments, the secondary functional groups can be selected so that segments of the copolymer with a secondary functional group can degrade faster than the primary functional group segments. The difference in degradation rate can be due to the secondary functional groups being more hydrolytically active than the primary functional group. In one embodiment, a secondary functional group can be selected such that a homopolymer including the secondary functional group has a higher degradation rate than a homopolymer including the primary functional group.
  • [0120]
    In an exemplary embodiment, the copolymer can be poly(L-lactide-co-glycolide). The primary functional group can be L-lactide and the secondary functional group can be glycolide. The weight percent of the glycolide in the copolymer can be at least 1%, 5%, 10%, 15%, 30%, 40%, or, at least 50%. In certain exemplary embodiments, the weight percent of glycolide group can be adjusted so that the degradation time of a stent, with or without dispersed bioceramic particles, can be less than 18 months, 12 months, 8 months, 5 months, or more narrowly, 3 months or less.
  • [0121]
    Further embodiments of the invention include formation of a bioceramic/polymer composite and fabrication of an implantable medical device therefrom. As indicated above, a composite of a polymer and bioceramic particles can be extruded to form a polymer construct, such as a tube. A stent can then be fabricated from the tube. The composite can be formed in a number of ways. In some embodiments, the composite can be formed by melt blending. In melt blending the bioceramic particles are mixed with a polymer melt. The particles can be mixed with the polymer melt using extrusion or batch processing.
  • [0122]
    In one embodiment, the bioceramic particles can be combined with a polymer in a powdered or granular form prior to melting of the polymer. The particles and polymer can be mixed using mechanical mixing or stirring such as agitation of the particles and polymer in a container or a mixer. The agitated mixture can then be heated to a temperature above the melt temperature of the polymer in an extruder or using batch processing.
  • [0123]
    However, a problem with the mechanical mixing or stirring techniques is that the polymer and particles may be separated into separate regions or layers. This is particularly a problem with respect to smaller particles such as nanoparticles. Additionally, obtaining a uniform dispersion by mixing particles with a polymer melt as described, is that particles can agglomerate or form clusters. The agglomeration of bioceramic particles makes it difficult to disperse the particles within the composite. The presence of larger clusters in the composite tends to result in a decrease in material performance. Such larger clusters can result in the formation of voids in a composite device, which are preferential sites for crack initiation and failure. The mechanical mixing in a conventional single screw extruder or in batch processing can be insufficient to break up the clusters, resulting in a nonuniform mixture of bioceramic particles and polymer.
  • [0124]
    Various embodiments of forming a composite may be employed to increase the uniformity of dispersion of bioceramic particles within a polymer in a composite. One set of embodiments may include forming a composite from a suspension of bioceramic particles and a polymer solution. A composite formed using a suspension may result in a composite having more uniformly dispersed particles than the mixing methods described above.
  • [0125]
    Another set of embodiments can include reducing the agglomeration of bioceramic particles by decreasing the surface energy between particles to improve the dispersion of particles in the composite. In some embodiments, the surface energy can be decreased by treating the bioceramic particles with a surface modifier. In still another set of embodiments, agglomeration can be reduced through mechanical mixing that applies shear stress to the particles sufficient to reduce the size of clusters of particles.
  • [0126]
    With respect to the first set of embodiments, bioceramic particles can be mixed with a polymer by solution blending in which a composite mixture of bioceramic particles and polymer is formed from a suspension of particles in a polymer solution. Certain embodiments of a method of forming an implantable medical device may include forming a suspension including a fluid, a polymer, and bioceramic particles. A “suspension” is a mixture in which particles are suspended or dispersed in a fluid. The fluid can be a solvent for the polymer so that the polymer is dissolved in the fluid. The particles can be mixed with the fluid before or after dissolving the polymer in the fluid.
  • [0127]
    Various mechanical mixing methods known to those of skill in the art may be used to disperse the bioceramic particles in the suspension. In one embodiment, the suspension can be treated with ultrasound, for example, by an ultrasonic mixer. The method may further include removing some or all of the fluid or separating the polymer and bioceramic particles from the fluid to obtain a composite including bioceramic particles dispersed within the polymer.
  • [0128]
    In some embodiments, the polymer and bioceramic particles can be separated from the fluid by combining the suspension with a second fluid that may be a poor solvent for the polymer. At least some of the polymer may be allowed to precipitate upon combining the suspension solution with the second fluid. In some embodiments, at least some of the bioceramic particles may precipitate from the suspension with the precipitated polymer to form a composite mixture.
  • [0129]
    The precipitated composite mixture may then be filtered out of the solvents. The filtered composite mixture can be dried to remove residual solvents. For example, the composite mixture can be dried in a vacuum oven or by blowing heated gas on the mixture.
  • [0130]
    Exemplary polymers may include, but are not limited to, poly (L-lactic acid), poly (DL-lactic acid), poly(lactide-coglycolide). Representative solvents for such polymers can include toluene and chloroform. Representative poor solvents for these polymers that may be used to precipitate the polymer include methanol, ethanol, isopropanol, and various alkanes such as hexane or heptane.
  • [0131]
    It is believed that in a suspension including bioceramic nanoparticles, the particles can have strong interactions with polymer chains in solution which can result in particles becoming encapsulated or surrounded by polymer chains. Thus, when the polymer is precipitated from the solution, the interactions of the particles with the polymer can overcome interactions of the particles with the solution so that the particles precipitate with the polymer.
  • [0132]
    Additionally, it has been observed that the both the degree of precipitation of particles and the degree of dispersion of particles within the precipitated polymer depends upon the amount of polymer dissolved in the solution. The degree of precipitation refers to the amount of particles that precipitate out of the suspension. The degree of dispersion of particles within the precipitated polymer refers to the degree of mixing of the particles with the polymer.
  • [0133]
    The amount of polymer can be quantified by the weight percent of the polymer in the suspension solution. In addition, the viscosity of the solution is also related to the amount of polymer in the solution. The higher the weight percent of dissolved polymer, the higher is the viscosity of the suspension solution.
  • [0134]
    For a given concentration of suspended particles, as weight percent of dissolved polymer or viscosity is reduced, the degree of precipitation of particles is reduced. This is likely due to the reduced interaction of the particles with the polymer chains. Thus, at lower weight percent of polymer or viscosity, the amount of particles precipitating can be relatively low.
  • [0135]
    Additionally, for a given concentration of suspended particles, as the weight percent of polymer or viscosity of the solution is increased beyond an observed range, the degree of dispersion of particles in the precipitated polymer tends to decrease. It is believed that at higher weight percent of polymer or higher viscosity, the interactions between polymer chains reduce the interaction of particles with polymer chains that cause particles to precipitate. For example, particles may be unable to move freely among the polymer chains.
  • [0136]
    A given suspension can have a particular combination of type of particles, particle concentration, and solvent. For this given suspension, the polymer weight percent or viscosity that can be varied to obtain both a desired degree of precipitation of particles and degree of dispersion of particles in the precipitated polymer. Thus, there may be a range of polymer weight percent or viscosity that can result in a desired degree of precipitation of particles and degree of dispersion of particles in precipitated polymer.
  • [0137]
    Additionally, the manner of combining the suspension with the poor solvent can also affect the degree of precipitation and degree of dispersion. For example, depositing a fine mist of small droplets into a poor solvent can more readily result in a desired degree of precipitation and degree of dispersion. Thus, the manner of combining the suspension with the poor solvent can influence the range of polymer weight percent or viscosity that results in a desired degree of precipitation and degree of dispersion.
  • [0138]
    In other embodiments, the polymer and bioceramic particles can be separated from the fluid in the suspension by evaporating the fluid in the suspension solution. In some embodiments, at least some of the bioceramic particles may be separated from the suspension solution along with the polymer upon evaporation to form the composite mixture. In one embodiment, the solvent can be removed by evaporation at high vacuum in a vacuum oven.
  • [0139]
    In further embodiments, the composite formed from the suspension solution can be conveyed into an extruder. The composite mixture may be extruded at a temperature above the melting temperature of the polymer and less than the melting temperature of the bioceramic particles. In some embodiments, the dried composite mixture may be broken into small pieces by, for example, chopping or grinding. Extruding smaller pieces of the composite mixture may lead to a more uniform distribution of the nanoparticles during the extrusion process.
  • [0140]
    The extruded composite mixture may then be formed into a polymer construct, such as a tube or sheet which can be rolled or bonded to form a tube. A medical device may then be fabricated from the construct. For example, a stent can be fabricated from a tube by laser machining a pattern in to the tube.
  • [0141]
    In another embodiment, a polymer construct may be formed from the composite mixture using an injection molding apparatus.
  • [0142]
    Preparation of a desired amount of precipitated composite mixture may require a large amount of solvent and precipitant. Therefore, in some embodiments, it may be advantageous to melt blend precipitated composite mixture with an amount of polymer in an extruder or in a batch process. The polymer can be the same or a different polymer of the precipitated composite mixture. For example, a relatively small amount of precipitated composite mixture that has a weight percent of bioceramic particles higher than is desired can be prepared. The precipitated composite mixture may be melt blended with an amount of biodegradable polymer to form a composite mixture than has a desired weight percent of bioceramic particles.
  • [0143]
    As indicated above, embodiments for increasing the dispersion of bioceramic particles in a composite can include decreasing the surface energy of particles with a surface modifier. Bioceramic particles tend to aggregate due to high surface energy resulting from strong interparticle interactions.
  • [0144]
    Certain embodiments can include processing a plurality of bioceramic particles with a non-reactive surface modifier to reduce the surface energy between the particles, hence, agglomeration of particles. A composite can then be formed with the processed bioceramic particles, the composite including the processed bioceramic particles dispersed within a polymer.
  • [0145]
    In some embodiments, the processing can include forming a suspension of bioceramic particles including a suitable solvent and a non-reactive surface modifier dissolved in the solvent. The non-reactive surface modifier tends to reduce surface energy between the particles, and thus, the fracture strength of the agglomerates or clusters of bioceramic particles. The non-reactive surface modifier may cause or facilitate the break-up or reduction in size of the agglomerates or clusters of particles.
  • [0146]
    Additionally, due to the decreased fracture strength, the agglomerates are more susceptible to break-up from application of conventional stirring techniques. In an embodiment, the breakdown of the agglomerates can be facilitated by mixing the suspension with an ultrasonic and/or high speed mixer known to one of skill in the art. The suspension can be mixed to obtain a desired degree of break-up of agglomerates. For example, the suspension can be mixed from one to five minutes, five to 30 minutes, 30 minutes to an hour, one hour to eight hours, or more than eight hours. The solvent may be removed and then mixed it with a polymer to form composite, e.g. by melt processing.
  • [0147]
    In one embodiment, the polymer of the composite can be dissolved in the solvent after forming the suspension with the non-reactive surface modifier and nano bioceramic. Alternatively, the polymer can be dissolved prior to adding the non-reactive surface modifier. After sufficient exposure of the bioceramic particles to the non-reactive surface modifier, the solvent can be removed to form a composite mixture of polymer and bioceramic particles. For example, the solvent can be removed as described above through precipitation or through evaporation.
  • [0148]
    Representative examples of non-reactive surface modifiers for treating bioceramic particles include, but are not limited to, stearic acid, polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide (PEO-b-PPO-b-PEO), and polyethylene oxide-b-polylactide. The non-reactive surface modifiers are used in amounts effective to prevent agglomeration of bioceramic particles. Generally, the non-reactive surface modifiers can be used in amounts of about 0.1 weight % to about 3 weight % by weight of the total composite mixture, more narrowly about 0.3 weight % to about 2 weight %, or more narrowly about 0.5 weight % to about 1 weight %.
  • [0149]
    As indicated above, further embodiments for decreasing agglomeration and increasing the dispersion of bioceramic particles in a composite can include processing a mixture of particles and polymer with mechanical methods sufficient to reduce agglomeration. Certain embodiments can include processing a mixture of a polymer and agglomerated bioceramic particles under high shear stress conditions. Some embodiments can include processing the mixture such that the particles are subjected to shear stress higher than the fracture strength of the agglomerated particles. In one embodiment, a polymer melt can blended or mixed with bioceramic particles in a manner that subjects the mixture to a shear stress higher than the fracture strength of agglomerates of bioceramic particles.
  • [0150]
    Generally, mixing a polymer melt with a melt viscosity η at a shear rate γ, subjects the melt and particles to a shear stress τ=η*γ. Thus, polymer/bioceramic mixture can be processed so that a maximum shear stress generated during the melt blending is higher than the fracture strength of the bioceramic particle agglomerates. Agglomerated particles may be mechanically broken down and more uniformly dispersed within the polymer.
  • [0151]
    As discussed above, the mechanical mixing of polymer and bioceramic particles provided by a single-screw extruder is generally insufficient to obtain a uniformly dispersed mixture of bioceramic particles with the polymer. The shear stress produced by a single screw extruder is typically lower than the fracture strength of bioceramic particle agglomerates.
  • [0152]
    Various kinds of mixing devices may be employed that can apply a shear stress higher than the fracture strength of agglomerates to a polymer melt. Mechanical blending devices that can apply a sufficiently high shear stress include, but are not limited to, a twin screw extruder or batch mixer. During blending, once the shear stress is higher than the fracture strength of bioceramic particles agglomerates, the agglomerates are broken down and more uniformly dispersed into the polymer. The polymer and bioceramic particles can be fed into a mechanical blending device separately and processed at high shear stress. Alternatively, a composite mixture of polymer and bioceramic particles can be fed into a mechanical blending device and processed at the high shear stress.
  • [0153]
    The polymer/bioceramic particle mixture can be processed at the sufficiently high shear stress for a time sufficient to reduce agglomeration and disperse the particles. For example, the mixture can be processed between about 5 min. to about 30 min., more narrowly about 8 min. to about 20 min., or more narrowly about 10 min to about 15 min.
  • [0154]
    In some embodiments, a composite of polymer and bioceramic particles formed by other methods disclosed herein can be processed at the high shear stress conditions. In one embodiment, the composite formed from a suspension solution through evaporation or precipitation can be processed at high shear stress conditions, for example, in a twin screw extruder or a batch mixer. In another embodiment, the composite formed with surface modified bioceramic particles can also be processed in this manner.
  • [0155]
    In some embodiments, bioceramic particles treated with a non-reactive surface modifier can be processed with a polymer to form a composite. The bioceramic particles can be treated by dispersing the bioceramic particles in a solution including the non-reactive surface modifier. Upon removal of the solvent from the solution, the treated particles can be processed in a mechanical mixing device such as an extruder. Since the fracture strength of clusters of agglomerated particles is decreased by the non-reactive surface modifier, even a conventional single screw extruder may facilitate break-up of the clusters, reducing agglomeration. In other embodiments, the treated particles and polymer can be processed in a device, such as a twin screw extruder or batch mixer, that subjects the particles and polymer to shear stress to shear stress greater than the fracture strength of clusters of untreated bioceramic particles.
  • [0156]
    Representative examples of polymers that may be used to fabricate an implantable medical device include, but are not limited to, poly(N-acetylglucosamine) (Chitin), Chitosan, poly(hydroxyvalerate), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(L-lactide), poly(D,L-lactic acid), poly(L-lactide-co-glycolide); poly(D,L-lactide), poly(caprolactone), poly(trimethylene carbonate), polyethylene amide, polyethylene acrylate, poly(glycolic acid-co-trimethylene carbonate), co-poly(ether-esters) (e.g. PEO/PLA), polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers other than polyacrylates, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), acrylonitrile-styrene copolymers, ABS resins, polyamides (such as Nylon 66 and polycaprolactam), polycarbonates, polyoxymethylenes, polyimides, polyethers, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose.
  • [0157]
    Additional representative examples of polymers that may be especially well suited for use in fabricating an implantable medical device according to the methods disclosed herein include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(butyl methacrylate), poly(vinylidene fluoride-co-hexafluororpropene) (e.g., SOLEF 21508, available from Solvay Solexis PVDF, Thorofare, N.J.), polyvinylidene fluoride (otherwise known as KYNAR, available from ATOFINA Chemicals, Philadelphia, Pa.), ethylene-vinyl acetate copolymers, and polyethylene glycol.
  • [0158]
    The examples and experimental data set forth below are for illustrative purposes only and are in no way meant to limit the invention. The following examples are given to aid in understanding the invention, but it is to be understood that the invention is not limited to the particular materials or procedures of examples. In examples 1-7, hydroxyapatite nano particles (HAP) are used as the bioceramic nanoparticles. In examples 8-9 calcium sulfate nanoparticles are used as the nanoparticles. The polymers used in the Examples were poly(L-lactic acid) (PLLA), poly(DL-lactic acid) (PDLLA), and poly(lactic acid-co-glycolide) (PLGA).
  • EXAMPLE 1 Prophetic Example of Solution Blending of Polymer and Bioceramic Particles
  • [0159]
    Step 1: Add bioceramic particles into suitable solvent, such as chloroform, acetone, etc. and stir to form a bioceramic particle suspension solution.
  • [0160]
    Step 2: Slowly add a polymer such as PLLA, PDLLA, PLGA into suspension solution and stir until polymer dissolves completely. In this step, the solution may still have a relatively low viscosity. However, the bioceramic particles should be well dispersed while stirring.
  • [0161]
    Step 3: Slowly add the polymer into solution again to gradually increase solution viscosity. Repeat this step as needed until the polymer is completely dissolved and reasonable solution viscosity is developed.
  • [0162]
    Step 4: Apply ultrasonic mixing to suspension solution for 15-30 min to further disperse all the HAP uniformly into the PLLA solution.
  • [0163]
    Step 6: Add suspension solution to methanol to precipitate polymer and particles.
  • EXAMPLE 2
  • [0164]
    Solution Blending of PLLA/HAP Composite (100:1 wt/wt)
  • [0165]
    Step 1: Added 50 mg HAP particles into 300 mL of chloroform and stirred for 10-30 minutes to form bioceramic particle suspension solution.
  • [0166]
    Step 2: Slowly added 5 g PLLA into suspension solution and stirred about 8 hours to dissolve all polymer.
  • [0167]
    Step 3: Applied ultrasonic mixing to suspension solution for 15-30 min to further disperse HAP particles into PLLA solution.
  • [0168]
    Step 4: Added suspension solution to 1 L methanol to precipitate polymer and particles.
  • [0169]
    Step 5: Filtered the precipitate and dried about 24 hours in vacuum oven at 60° C. End product is PLLA/HAP composite.
  • [0170]
    Composites were also made with 2 wt % and 5 wt % HAP.
  • [0171]
    Mechanical Properties and Morphology of PLLA/HAP Composite (100:1 wt/wt)
  • [0172]
    Tensile testing of the composite samples and a pure PLLA were performed using an Instron tensile tester obtained from Instron in Canton, Mass. Test samples were prepared by hot pressing the PLLA/HAP composites and pure polymer to a thin film at 193° C. for 60 seconds. Testing bars were cut from the thin film and tested. The peak stress at break, the strain at break, and the Young's modulus were measured. The draw rate was about 0.5 in/min.
  • [0173]
    FIGS. 4-6 illustrate tensile testing results for pure PLLA and PLLA/HAP composites with 1 wt % HAP. FIG. 4 depicts the peak stress for the two samples. PLLA/HAP composites have a higher peak stress than the pure PLLA. FIG. 5 depicts the % strain at break for the two samples. The 1 wt % composite had a higher % strain at break than the pure PLLA. FIG. 6 depicts Young's modulus for the two samples. The 1 wt % samples had a higher Young's modulus than the pure PLLA.
  • EXAMPLE 3
  • [0174]
    Solution Blending of PLLA/HAP Composite (2:1 wt/wt) as HAP Intermedium Mixture
  • [0175]
    Step 1: Added 25 g HAP particles to 3 L chloroform and stirred for 10-30 minutes to form bioceramic particle suspension solution.
  • [0176]
    Step 2: Slowly added 50 g PLLA into suspension solution and stirred about 8 hours to dissolve all polymer.
  • [0177]
    Step 3: Applied ultrasonic mixing for 15-30 min to further disperse HAP particles into PLLA solution.
  • [0178]
    Step 4: Added suspension solution to 9 L methanol to precipitate particles and polymer.
  • [0179]
    Step 5: Filtered the precipitate and dried about 24 hours in vacuum oven at 60° C. End product is PLLA/HAP composite.
  • [0180]
    Extrusion of Precipitated PLLA/HAP (2:1 wt/wt) with PLLA
  • [0181]
    Step 1: Broke 2:1 wt/wt composite into small pieces
  • [0182]
    Step 2: Mixed 24 g of broken up composite and 376 g PLLA.
  • [0183]
    Step 3: Extruded mixture at 216° C.
  • EXAMPLE 4
  • [0184]
    Extrusion of Precipitated PLGA/HAP (2:1 wt/wt) with PLGA
  • [0185]
    Step 1: Broke PLGA/HAP composite into small pieces
  • [0186]
    Step 2: Mixed 12 g broken up PLGA/HAP composite and 396 g PLGA.
  • [0187]
    Step 3: Extruded mixture at 216° C.
  • EXAMPLE 5
  • [0188]
    As discussed above, to further improve mechanical properties of a bioceramic and polymer composite, the interfacial adhesion can be enhanced. The adhesion between bioceramic particles and a biodegradable polymer can be improved by coating at least a portion of the surfaces of the bioceramic particles with an adhesion promoter such as 3-aminopropyltrimethoxysilane and 3-aminopropyltriethoxysilane.
  • [0189]
    Example of the modification of HAP:
  • [0190]
    Step 1: Added 100 ml distillated water to 1900 ml Ethanol and stirred for 15-30 min.
  • [0191]
    Step 2: Added 20 g 3-aminopropyltrimethoxysilane to water-ethanol mixture and stirred for 1 h.
  • [0192]
    Step 3: Added 20 g HAP and stirred for 2 h.
  • [0193]
    Step 4: Centrifuged the modified HAP from solution.
  • [0194]
    Step 5: Dried HAP about 8 hours in vacuum oven.
  • EXAMPLE 6
  • [0195]
    A stent was fabricated from PLGA/nanoparticle composite tubing. Prior to cutting a stent pattern, the tubing was expanded at 109° C. in a blow molder to increase radial strength. A stent pattern was cut in the expanded tubing using an ultra-fast pulse laser. The stent was crimped at 30° C. After crimping, the stent was cold sterilized.
  • EXAMPLE 7
  • [0196]
    The mechanical properties of a stent fabricated from a PLGA/nanoparticle HAP composite were tested on an Instron compression tester. The recoil of stents was recorded after inflation and deflation of stent.
  • [0197]
    FIGS. 7 and 8 illustrate compression testing results for PLGA/HAP stent (100:1 wt/wt). The compression testing results for 100% PLGA is also included for comparison. FIG. 7 shows that the average radial strength of PLGA/HAP stent is about 11% higher than that of the 100% PLGA stent. FIG. 8 shows that the compression modulus of PLGA/nano HAP stent increased by about 23% over the 100% PLGA stent.
  • [0198]
    FIG. 9 shows the recoil of PLGA/nano HAP stent is about 15% less than the PLGA stent.
  • EXAMPLE 8
  • [0199]
    Stents were fabricated from a bioceramic/polymer composite with a matrix of PLGA copolymer. Calcium sulfate nanoparticles, which were pretreated by PEG-PPG-PEG surface modifier, were mixed with the copolymer matrix. PEG refers to polyethylene glycol and PPG refers to polypropylene glycol. The copolymer had 85 wt % L-lactide and 15 wt % GA. The composite was fabricated according to methods described herein. The stents were fabricated from tubes made from the composite and the tubes was radially expanded. The expanded tubes were laser cut to form stents.
  • [0200]
    Stents were fabricated and tested having a ratio of copolymer to particles of 100:1 by weight. Five stent samples were used for each testing (compression, recoil or expansion testing). at a zero time point (after fabrication) and after 16 hours of accelerated aging. Accelerated aging refers to aging at 40° C.
  • [0201]
    The zero time point samples were subjected to compression testing. Compression tests were performed with an Instron testing machine obtained from Instron in Canton, Mass. A stent sample was placed between two flat plates. The plates were adjusted so that the distance between the plates was the diameter of the stent in an uncompressed state. The plates were then adjusted to compress the stent by 10%, 15%, 25%, and 50% of the uncompressed plate distance. A resistance force, the amount force in units of Newtons/mm that was necessary to keep the stent at each compression distance, was measured. The resistance force corresponds to a measure of the radial strength (Rs). The modulus was also measured. Table 1 provides the compression test results for the 100:1 samples at zero time point. The Rs and modulus correspond to 50% compression.
    TABLE 1
    Compression test results for 100:1 samples at zero time point.
    Stent # Rs (psi) Modulus (psi)
    1 5.867 365.5
    2 5.443 291.5
    3 6.027 316.9
    4 5.879 324.2
    5 5.539 310.1
    Avg 5.751 321.6
    Std dev 0.248 27.360
  • [0202]
    The stent samples were subjected to recoil testing at both time points for each bioceramic composition. Each stent sample was deployed inside a length of Tecoflex elastic tubing. Tecoflex tubing can be obtained from Noveon, Inc., Cleveland, Ohio. The inside diameter (ID) of the Tecoflex tubing was 0.118 in and the outside diameter (OD) was 0.134 in. The ID of the sheath to hold the stent after crimping was 0.053 in. The stents were deployed to an outer diameter of 3.0 mm by inflating the balloon. The balloon was deflated, allowing the stent to recoil. The diameter of the recoiled stent was then measured.
  • [0203]
    The percent recoil was calculated from:
    % Recoil=(Inflated Diameter−Deflated Diameter)/Inflated Diameter×100%
  • [0204]
    The Inflated Diameter is the diameter of a deployed stent prior to deflating the balloon and the Deflated Diameter is the diameter of the recoiled stent. The deployment of the stent also results in an increase in length of the stent. The percent change in length was calculated from:
    % Length change=(Crimped length−Deployed length)/Crimped length×100%
  • [0205]
    Table 2 provides the results of the recoil test for the five 100:1 stent samples at zero time point. As shown in Table 1, the outside diameter (OD) of the stent when the balloon was inflated and deflated was measured at a proximal end, a middle, and distal end of the stent. ODwt refers to the outside diameter with tecoflex tubing and ODS refers to the outside diameter with stent only. The % Total Recoil given is the average of the recoil calculated at each point along the length of the stent.
    TABLE 2
    Recoil test results for 100:1 stent samples at zero time point.
    Crimp Inflated @ 8 atm Deflated Dimensions
    Tecoflex Tecoflex Stent Stent Prox Mid Distal Prox Mid Distal % %
    DWT DWT L L OD OD OD Stent L OD OD OD Total Length
    Stent # Prox Dist (mm) (mm) (mm) (mm) (mm) (mm) (mm) (mm) (mm) Recoil Change
    1 0.375 0.370 12.796 12.384 3.690 3.774 3.802 12.392 3.448 3.504 3.529 7.7% 3.2%
    2 0.368 0.378 12.833 12.529 3.792 3.785 3.811 12.450 3.541 3.487 3.496 8.4% 3.0%
    3 0.368 0.374 12.817 12.553 3.835 3.886 3.871 12.720 3.618 3.561 3.519 8.5% 0.8%
    4 0.375 0.370 12.863 12.492 3.792 3.806 3.871 12.774 3.653 3.673 3.644 4.8% 0.7%
    5 0.365 0.370 12.793 12.421 3.803 3.815 3.856 12.407 3.579 3.576 3.640 6.5% 3.0%
    ODwT 3.813 3.565 AVG 7.2% 2.1%
    ODS 3.441 3.193 Std 1.6% 1.3%
    Dev
  • [0206]
    The stents were subject to expansion testing at both time points. Each stent sample was deployed to an outer diameter of first 3.0 mm, then 3.5 mm, and then 4.0 mm. The number of cracks in the stents were counted at each deployment diameter.
  • [0207]
    Table 3 provides the number of cracks observed in the 100:1 stent samples at zero time point when deployed at a diameter of 3.5 mm. The columns refer to the size of the cracks: “Micro” refers to micro-sized cracks, “<25%” refers to cracks less than 25% of the strut width, “<50%” refers to cracks less than 50% of the strut width, and “>50%” refers to cracks greater than 50% of the strut width. “A” refers to the “v-shaped” region or bending region of struts and “B” refers to a spider region at the intersection of 5 struts. The regions can be seen in FIGS. 10A-D. No broken struts were observed at either 3.5 mm or 4.0 mm deployment diameters. FIGS. 10A-D depict photographic images of the 100:1 stent sample 1 at zero time point before expansion, expanded to 3.5 mm, after recoil, and after expansion to 4.0 mm, respectively.
    TABLE 3
    Number of cracks observed at 3.5 mm deployment
    for 100:1 stent samples at zero time point.
    Stents Deployed to 3.5 mm
    Stent # Micro <25% <50% >50%
    1
    A 4 2
    B
    2
    A 2
    B
    3
    A 4
    B
    4
    A
    B
    5
    A 1
    B
  • [0208]
    Test Results for 100:1 Stent Samples at 16 Hours of Accelerated Aging
  • [0209]
    Table 4 provides the results of the recoil test for the 100:1 stent samples at 16 hours of accelerated aging. Tables 5A-B provide the number of cracks observed in the 100:1 stent samples at 16 hours of accelerated aging when deployed at a diameter of 3.5 mm and 4.0 mm, respectively. No broken struts were observed at either deployment diameter. FIGS. 11A-D depict photographic images of the 100:1 stent sample 1 at 16 hours of accelerated aging before expansion, expanded to 3.5 mm, after recoil, and after expansion to 4.0 mm, respectively.
    TABLE 4
    Recoil test results for 100:1 stent samples at 16 hours of accelerated aging.
    Crimp Dimensions Inflated @ 8 atm Dimensions Deflated Dimensions
    Tecoflex Tecoflex Stent Stent Prox Mid Distal Prox Mid Distal % %
    DWT DWT L L OD OD OD Stent L OD OD OD Total Length
    Stent # Prox Dist (mm) (mm) (mm) (mm) (mm) (mm) (mm) (mm) (mm) Recoil Change
    1 0.372 0.377 12.683 12.133 3.900 3.834 3.836 12.311 3.508 3.520 3.522 9.8% 2.9%
    2 0.380 0.383 12.830 12.306 3.870 3.809 3.780 12.380 3.623 3.546 3.584 6.8% 3.5%
    3 0.374 0.372 12.924 12.574 3.845 3.804 3.783 12.620 3.477 3.448 3.422 10.5% 2.4%
    4 0.373 0.375 12.806 12.411 3.933 3.874 3.881 12.486 3.526 3.508 3.508 10.8% 2.5%
    5 0.381 0.382 12.745 12.358 3.853 3.799 3.809 12.570 3.482 3.489 3.471 9.9% 1.4%
    ODwT 3.841 3.509 AVG 9.6% 2.5%
    ODS 3.464 3.132 Std Dev 1.6% 0.8%
  • [0210]
    TABLE 5A
    Number of cracks observed for 100:1 stent samples at 16
    hours of accelerated aging deployed at 3.5 mm.
    Stents Deployed to 3.5 mm
    Stent # Micro <25% <50% >50%
    1
    A 2 1
    B 1
    2
    A
    B
    3
    A 2 1
    B
    4
    A 1
    B
    5
    A 7
    B 1
  • [0211]
    TABLE 5B
    Number of cracks observed for stents deployed at 4.0 mm for
    100:1 stent samples at 16 hours of accelerated aging.
    Stents Deployed to 4.0 mm
    Stent # Micro <25% <50% >50%
    1
    A 6 1
    B 3 1
    2
    A
    B 1
    3
    A 5 1
    B 1
    4
    A 1 1
    B 2 1
    5
    A 4 2
    B 1
  • EXAMPLE 9
  • [0212]
    A stent was fabricated from a polymer/bioceramic composite. The matrix was a PLGA copolymer. Calcium sulfate nanoparticles were mixed with the copolymer matrix. The copolymer was 50 wt % L-lactide and 50 wt % glycolide. The ratio of copolymer to particles was 100:3 by weight. The composite was fabricated according to methods described herein. A tube was fabricated from the composite and the tube was radially expanded. The expanded tube was laser cut to form a stent. The expected degradation time for the composite stent is about 3-5 months.
  • EXAMPLE 10
  • [0213]
    The following example illustrates formation of a polymer/bioceramic particle composite with surface modified bioceramic particles.
  • [0214]
    Step 1: A solution was formed by dissolving 8 g stearic acid (surface modifier) in 200 ml isopropanol (solvent).
  • [0215]
    Step 2: 20 g Calcium sulfate (CS) nanoparticles were added to the solution to form a suspension. The suspension was stirred for 1 h.
  • [0216]
    Step 3: The suspension was subjected to ultrasonic mixing for 30-60 min to reduce the agglomeration of nanoparticles.
  • [0217]
    Step 4: The solvent was removed through evaporation at high vacuum.
  • [0218]
    Step 5: A polymer/nanoparticle composite was prepared by blending two portions of the modified calcium sulfate nanoparticles and 100 portions of a PLLA composite mixture which contained uniformly dispersed nanoparticles in the PLLA matrix.
  • EXAMPLE 11
  • [0219]
    Preparation of PEO-b-PPO-b-PEO Modified Calcium Sulfate Master Batch Material
  • [0220]
    Step 1: A solution was formed by dissolving 20 g PEO-b-PPO-b-PPO (surface modifier) in 400 ml chloroform (solvent).
  • [0221]
    Step 2: 20 g Calcium sulfate nanoparticles were added to the solution to form a suspension. The suspension was stirred for 1 h.
  • [0222]
    Step 3: The suspension was subjected to ultrasonic mixing for 30 min to reduce the agglomeration of nanoparticles.
  • [0223]
    Step 4: A polymer/nanoparticle composite was prepared by adding 20 g LPLG to the modified calcium sulfate nanoparticles. The reaction mixture was stirred overnight till all LPLG dissolved into solution.
  • [0224]
    Step 5: The solvent was removed through evaporation at high vacuum.
  • EXAMPLE 12
  • [0225]
    LPLG/Modified Calcium Sulfate Tubing Preparation and Morphology Observation
  • [0226]
    Step 1: A solution was formed by dissolving 20 g PEO-b-PPO-b-PPO (surface modifier) in 400 ml chloroform (solvent).
  • [0227]
    Step 2: 20 g Calcium sulfate nanoparticles were added to the solution to form a suspension. The suspension was stirred for 1 h.
  • [0228]
    Step 3: The suspension was subjected to ultrasonic mixing for 30 min to reduce the agglomeration of nanoparticles.
  • [0229]
    Step 4: The solvent was removed through evaporation at high vacuum.
  • [0230]
    Step 5: A polymer/nanoparticle composite was prepared by mixing the modified calcium sulfate nanoparticles with 1000 g LPLG. The tubing was prepared through extrusion using single screw extruder.
  • [0231]
    FIG. 12A shows s SEM photographic image of an LPLG/unmodified CS particle composite. The CS particles size range from 1 to 50 μm, with most particles between 2 to 30 μm. FIG. 12B illustrates a photographic image of an LPLG/modified CS particle composite with particles modified with PEO-b-PPO-b-PEO. The CS particles size range from 0.1 to 10 μm, where most of the particles are from 0.3 to 6 μm.
  • EXAMPLE 13
  • [0232]
    Preparation of Stearic Acid Modified Calcium Sulfate Master Batch Material
  • [0233]
    Step 1: A solution was formed by dissolving 16 g stearic acid (surface modifier) in 400 ml chloroform.
  • [0234]
    Step 2: 20 g Calcium sulfate nanoparticles were added to the solution to form a suspension. The suspension was stirred for 1 h.
  • [0235]
    Step 3: The suspension was subjected to ultrasonic mixing for 30 min.
  • [0236]
    Step 5: A polymer/nanoparticle composite was prepared by adding 20 g LPLG to the modified calcium sulfate nanoparticles. The reaction mixture was stirred overnight till all LPLG dissolved into solution.
  • [0237]
    Step 4: The solvent was removed through evaporation at high vacuum.
  • EXAMPLE 14
  • [0238]
    LPLG/Modified Calcium Sulfate Tubing Preparation and Morphology Observation
  • [0239]
    Step 1: A solution was formed by dissolving 16 g stearic acid (surface modifier) in 400 ml chloroform (solvent).
  • [0240]
    Step 2: 20 g Calcium sulfate nanoparticles were added to the solution to form a suspension. The suspension was stirred for 1 h.
  • [0241]
    Step 3: The suspension was subjected to ultrasonic mixing for 30 min to reduce the agglomeration of nanoparticles.
  • [0242]
    Step 4: The solvent was removed through evaporation at high vacuum.
  • [0243]
    Step 5: A polymer/nanoparticle composite was prepared by mixing the modified calcium sulfate nanoparticles with 1000 g LPLG. The reaction mixture was stirred overnight till all LPLG dissolved into solution.
  • [0244]
    Step 6: The cross-section morphology of the tubing was observed by SEM (FIG. 1C).
  • [0245]
    FIG. 12C shows a photographic image of LPLG/stearic acid modified CS particle composite, which is similar to the morphology of LPLG/PEO-b-PPO-b-PEO modified CS particle composite. The CS particles sizes range from 0.1 to 10 μm, where most of them are from 0.5 to 6 μm.
  • EXAMPLE 15
  • [0246]
    LPLG material and surface modified or non-modified CS nano particles were mixed and extruded through a twin screw extruder. CS content in the extruded material is roughly 2%. The morphology of the extruded material was observed by SEM
  • [0247]
    FIG. 13A illustrates a photographic image of extruded LPLG/CS composite using a twin screw extruder. Overall, the CS particles sizes range from 0.2 to 20 μm with most of the particles from 0.5 to 5 μm. As a comparison, FIG. 13B shows a photographic image of LPLG/CS particle composite using a single screw extruder with low shear stress. Overall, the CS particles sizes range from 1 to 50 μm, where most of them are from 2 to 30 μm. FIG. 13C shows an image of an LPLG/PEO-b-PPO-b-PEO modified CS particles composite by twin screw extruder at with high shear stress, the CS particles sizes range from 0.1 to 10 μm, where most of them are from 0.2 to 3 μm.
  • [0248]
    While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4321711 *12 Oct 197930 Mar 1982Sumitomo Electric Industries, Ltd.Vascular prosthesis
US4633873 *26 Apr 19846 Jan 1987American Cyanamid CompanySurgical repair mesh
US4656083 *11 Mar 19857 Apr 1987Washington Research FoundationPlasma gas discharge treatment for improving the biocompatibility of biomaterials
US4718907 *20 Jun 198512 Jan 1988Atrium Medical CorporationVascular prosthesis having fluorinated coating with varying F/C ratio
US4722335 *20 Oct 19862 Feb 1988Vilasi Joseph AExpandable endotracheal tube
US4723549 *18 Sep 19869 Feb 1988Wholey Mark HMethod and apparatus for dilating blood vessels
US4732152 *5 Dec 198522 Mar 1988Medinvent S.A.Device for implantation and a method of implantation in a vessel using such device
US4733665 *7 Nov 198529 Mar 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4739762 *3 Nov 198626 Apr 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4740207 *10 Sep 198626 Apr 1988Kreamer Jeffry WIntralumenal graft
US4800882 *13 Mar 198731 Jan 1989Cook IncorporatedEndovascular stent and delivery system
US4816339 *28 Apr 198728 Mar 1989Baxter International Inc.Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
US4818559 *29 Jul 19864 Apr 1989Sumitomo Chemical Company, LimitedMethod for producing endosseous implants
US4902289 *9 Aug 198820 Feb 1990Massachusetts Institute Of TechnologyMultilayer bioreplaceable blood vessel prosthesis
US4994298 *18 Apr 199019 Feb 1991Biogold Inc.Method of making a biocompatible prosthesis
US5084065 *10 Jul 198928 Jan 1992Corvita CorporationReinforced graft assembly
US5085629 *27 Sep 19894 Feb 1992Medical Engineering CorporationBiodegradable stent
US5100429 *20 Oct 198931 Mar 1992C. R. Bard, Inc.Endovascular stent and delivery system
US5104410 *22 Oct 199014 Apr 1992Intermedics Orthopedics, IncSurgical implant having multiple layers of sintered porous coating and method
US5108417 *14 Sep 199028 Apr 1992Interface Biomedical Laboratories Corp.Anti-turbulent, anti-thrombogenic intravascular stent
US5108755 *27 Apr 198928 Apr 1992Sri InternationalBiodegradable composites for internal medical use
US5192311 *13 Aug 19909 Mar 1993Angeion CorporationMedical implant and method of making
US5197977 *30 Apr 199230 Mar 1993Meadox Medicals, Inc.Drug delivery collagen-impregnated synthetic vascular graft
US5279594 *23 May 199018 Jan 1994Jackson Richard RIntubation devices with local anesthetic effect for medical use
US5282860 *8 Oct 19921 Feb 1994Olympus Optical Co., Ltd.Stent tube for medical use
US5289831 *21 Apr 19921 Mar 1994Vance Products IncorporatedSurface-treated stent, catheter, cannula, and the like
US5290271 *29 Jul 19931 Mar 1994Jernberg Gary RSurgical implant and method for controlled release of chemotherapeutic agents
US5306286 *1 Feb 199126 Apr 1994Duke UniversityAbsorbable stent
US5306294 *5 Aug 199226 Apr 1994Ultrasonic Sensing And Monitoring Systems, Inc.Stent construction of rolled configuration
US5383925 *14 Sep 199224 Jan 1995Meadox Medicals, Inc.Three-dimensional braided soft tissue prosthesis
US5385580 *21 Sep 199231 Jan 1995Meadox Medicals, Inc.Self-supporting woven vascular graft
US5389106 *29 Oct 199314 Feb 1995Numed, Inc.Impermeable expandable intravascular stent
US5399666 *21 Apr 199421 Mar 1995E. I. Du Pont De Nemours And CompanyEasily degradable star-block copolymers
US5407609 *17 May 199318 Apr 1995Southern Research InstituteMicroencapsulation process and products therefrom
US5502158 *22 Sep 199226 Mar 1996Ecopol, LlcDegradable polymer composition
US5591199 *7 Jun 19957 Jan 1997Porter; Christopher H.Curable fiber composite stent and delivery system
US5591607 *6 Jun 19957 Jan 1997Lynx Therapeutics, Inc.Oligonucleotide N3→P5' phosphoramidates: triplex DNA formation
US5593403 *14 Sep 199414 Jan 1997Scimed Life Systems Inc.Method for modifying a stent in an implanted site
US5593434 *7 Jun 199514 Jan 1997Advanced Cardiovascular Systems, Inc.Stent capable of attachment within a body lumen
US5599301 *22 Nov 19934 Feb 1997Advanced Cardiovascular Systems, Inc.Motor control system for an automatic catheter inflation system
US5599922 *18 Mar 19944 Feb 1997Lynx Therapeutics, Inc.Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5605696 *30 Mar 199525 Feb 1997Advanced Cardiovascular Systems, Inc.Drug loaded polymeric material and method of manufacture
US5607442 *13 Nov 19954 Mar 1997Isostent, Inc.Stent with improved radiopacity and appearance characteristics
US5607467 *23 Jun 19934 Mar 1997Froix; MichaelExpandable polymeric stent with memory and delivery apparatus and method
US5618299 *8 Aug 19958 Apr 1997Advanced Cardiovascular Systems, Inc.Ratcheting stent
US5707385 *16 Nov 199413 Jan 1998Advanced Cardiovascular Systems, Inc.Drug loaded elastic membrane and method for delivery
US5711763 *30 Jun 199527 Jan 1998Tdk CorporationComposite biological implant of a ceramic material in a metal substrate
US5716981 *7 Jun 199510 Feb 1998Angiogenesis Technologies, Inc.Anti-angiogenic compositions and methods of use
US5725549 *12 Sep 199610 Mar 1998Advanced Cardiovascular Systems, Inc.Coiled stent with locking ends
US5726297 *5 Jun 199510 Mar 1998Lynx Therapeutics, Inc.Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5728751 *25 Nov 199617 Mar 1998Meadox Medicals, Inc.Bonding bio-active materials to substrate surfaces
US5733326 *28 May 199631 Mar 1998Cordis CorporationComposite material endoprosthesis
US5733330 *13 Jan 199731 Mar 1998Advanced Cardiovascular Systems, Inc.Balloon-expandable, crush-resistant locking stent
US5733564 *12 Apr 199431 Mar 1998Leiras OyMethod of treating endo-osteal materials with a bisphosphonate solution
US5733925 *28 Oct 199631 Mar 1998Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
US5741881 *25 Nov 199621 Apr 1998Meadox Medicals, Inc.Process for preparing covalently bound-heparin containing polyurethane-peo-heparin coating compositions
US5855612 *10 May 19965 Jan 1999Ohta Inc.Biocompatible titanium implant
US5855618 *13 Sep 19965 Jan 1999Meadox Medicals, Inc.Polyurethanes grafted with polyethylene oxide chains containing covalently bonded heparin
US5858746 *25 Jan 199512 Jan 1999Board Of Regents, The University Of Texas SystemGels for encapsulation of biological materials
US5865814 *6 Aug 19972 Feb 1999Medtronic, Inc.Blood contacting medical device and method
US5868781 *22 Oct 19969 Feb 1999Scimed Life Systems, Inc.Locking stent
US5873904 *24 Feb 199723 Feb 1999Cook IncorporatedSilver implantable medical device
US5874101 *14 Apr 199723 Feb 1999Usbiomaterials Corp.Bioactive-gel compositions and methods
US5874109 *4 Sep 199723 Feb 1999The Trustees Of The University Of PennsylvaniaIncorporation of biological molecules into bioactive glasses
US5874165 *27 May 199723 Feb 1999Gore Enterprise Holdings, Inc.Materials and method for the immobilization of bioactive species onto polymeric subtrates
US5876743 *22 Sep 19972 Mar 1999Den-Mat CorporationBiocompatible adhesion in tissue repair
US5877263 *25 Nov 19962 Mar 1999Meadox Medicals, Inc.Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents
US5879713 *23 Jan 19979 Mar 1999Focal, Inc.Targeted delivery via biodegradable polymers
US5888533 *21 Nov 199730 Mar 1999Atrix Laboratories, Inc.Non-polymeric sustained release delivery system
US5891192 *22 May 19976 Apr 1999The Regents Of The University Of CaliforniaIon-implanted protein-coated intralumenal implants
US5897955 *21 Aug 199827 Apr 1999Gore Hybrid Technologies, Inc.Materials and methods for the immobilization of bioactive species onto polymeric substrates
US6010445 *12 Nov 19974 Jan 2000Implant Sciences CorporationRadioactive medical device and process
US6015541 *3 Nov 199718 Jan 2000Micro Therapeutics, Inc.Radioactive embolizing compositions
US6042875 *2 Mar 199928 Mar 2000Schneider (Usa) Inc.Drug-releasing coatings for medical devices
US6169170 *3 Sep 19972 Jan 2001Lynx Therapeutics, Inc.Oligonucleotide N3′→N5′Phosphoramidate Duplexes
US6171609 *23 Oct 19959 Jan 2001Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
US6174330 *1 Aug 199716 Jan 2001Schneider (Usa) IncBioabsorbable marker having radiopaque constituents
US6177523 *14 Jul 199923 Jan 2001Cardiotech International, Inc.Functionalized polyurethanes
US6183505 *11 Mar 19996 Feb 2001Medtronic Ave, Inc.Method of stent retention to a delivery catheter balloon-braided retainers
US6187045 *10 Feb 199913 Feb 2001Thomas K. FehringEnhanced biocompatible implants and alloys
US6511748 *6 Jan 199928 Jan 2003Aderans Research Institute, Inc.Bioabsorbable fibers and reinforced composites produced therefrom
US6517888 *28 Nov 200011 Feb 2003Scimed Life Systems, Inc.Method for manufacturing a medical device having a coated portion by laser ablation
US6527801 *13 Apr 20004 Mar 2003Advanced Cardiovascular Systems, Inc.Biodegradable drug delivery material for stent
US6537589 *25 Jul 200025 Mar 2003Kyung Won Medical Co., Ltd.Calcium phosphate artificial bone as osteoconductive and biodegradable bone substitute material
US6676697 *17 Mar 199813 Jan 2004Medinol Ltd.Stent with variable features to optimize support and method of making such stent
US6679980 *13 Jun 200120 Jan 2004Advanced Cardiovascular Systems, Inc.Apparatus for electropolishing a stent
US6689375 *14 Oct 200210 Feb 2004Coripharm Medizinprodukte Gmbh & Co. KgResorbable bone implant material and method for producing the same
US6689823 *31 Mar 200010 Feb 2004The Brigham And Women's Hospital, Inc.Nanocomposite surgical materials and method of producing them
US6695920 *27 Jun 200124 Feb 2004Advanced Cardiovascular Systems, Inc.Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US6706273 *14 Aug 200016 Mar 2004Ivoclar Vivadent AgComposition for implantation into the human and animal body
US6709379 *2 Nov 199923 Mar 2004Alcove Surfaces GmbhImplant with cavities containing therapeutic agents
US6846323 *15 May 200325 Jan 2005Advanced Cardiovascular Systems, Inc.Intravascular stent
US20020002399 *8 May 20013 Jan 2002Huxel Shawn ThayerRemovable stent for body lumens
US20020004060 *17 Jul 199810 Jan 2002Bernd HeubleinMetallic implant which is degradable in vivo
US20020004101 *30 Aug 200110 Jan 2002Schneider (Usa) Inc.Drug coating with topcoat
US20030033001 *27 Apr 200113 Feb 2003Keiji IgakiStent holding member and stent feeding system
US20070026069 *26 Mar 20041 Feb 2007Shastri Venkatram PBiommetic hierarchies using functionalized nanoparticles as building blocks
US20080063685 *13 Sep 200613 Mar 2008Yunbing WangDegradable polymeric implantable medical devices with continuous phase and discrete phase
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US8414638 *12 Mar 20089 Apr 2013Abbott Cardiovascular Systems Inc.Method for fabricating a polymer stent with break-away links for enhanced stent retenton
US842559111 Jun 200723 Apr 2013Abbott Cardiovascular Systems Inc.Methods of forming polymer-bioceramic composite medical devices with bioceramic particles
US865808228 Aug 201225 Feb 2014Abbott Cardiovascular Systems Inc.Method of fabricating stents from blow molded tubing
US8852263 *12 Jul 20127 Oct 2014Abbott Cardiovascular Systems Inc.Stent with nucleating agent
US899897828 Sep 20077 Apr 2015Abbott Cardiovascular Systems Inc.Stent formed from bioerodible metal-bioceramic composite
US9119905 *15 Aug 20141 Sep 2015Elixir Medical CorporationBiodegradable endoprostheses and methods for their fabrication
US914448719 Apr 201329 Sep 2015Abbott Cardiovascular Systems Inc.Polymer-bioceramic composite medical devices with bioceramic particles having grafted polymers
US92593398 Apr 201516 Feb 2016Elixir Medical CorporationBiodegradable endoprostheses and methods of their fabrication
US938127526 Jan 20155 Jul 2016Orthovita, Inc.Bioactive load-bearing composites
US93812774 Apr 20145 Jul 2016Purac Biochem BvResorbable and biocompatible fibre glass compositions and their uses
US939908624 Jul 200926 Jul 2016Warsaw Orthopedic, IncImplantable medical devices
US948058827 Apr 20151 Nov 2016Elixir Medical CorporationBiodegradable endoprostheses and methods of their fabrication
US956637121 Jul 201514 Feb 2017Elixir Medical CorporationBiodegradable endoprostheses and methods for their fabrication
US966282129 Apr 201530 May 2017Orthovita, Inc.Bioactive composites of polymer and glass and method for making same
US973081915 Jul 201515 Aug 2017Elixir Medical CorporationBiodegradable endoprostheses and methods of their fabrication
US20090088834 *28 Sep 20072 Apr 2009Abbott Cardiovascular Systems Inc.Stent formed from bioerodible metal-bioceramic composite
US20090234432 *12 Mar 200817 Sep 2009Pacetti Stephen DPolymer Stent With Break-Away Links For Enhanced Stent Retention
US20100168798 *13 Oct 20091 Jul 2010Clineff Theodore DBioactive composites of polymer and glass and method for making same
US20110238155 *8 Jun 201129 Sep 2011Abbott Cardiovascular Systems Inc.Stent formed from bioerodible metal-bioceramic composite
US20120277358 *12 Jul 20121 Nov 2012Abbott Cardiovascular Systems Inc.Stent with nucleating agent
US20140039603 *30 Sep 20136 Feb 2014Abbott Cardiovascular Systems Inc.Bioabsorbable scaffolds made from composites
US20150025619 *15 Aug 201422 Jan 2015Elixir Medical CorporationBiodegradable endoprostheses and methods for their fabrication
US20150328373 *19 May 201419 Nov 2015Abbott Cardiovascular Systems Inc.Additives To Increase Degradation Rate Of A Biodegradable Scaffolding And Methods Of Forming Same
EP2397306A3 *9 Dec 200827 Mar 2013Abbott Cardiovascular Systems Inc.Method of fabricating a stent from blow molded tubing
EP2647484A1 *9 Dec 20089 Oct 2013Abbott Cardiovascular Systems Inc.Method of fabricating a stent from blow molded tubing
EP2998358A4 *16 May 20138 Feb 2017Sofsera CorpBiodegradable material
WO2012100651A1 *18 Jan 20122 Aug 2012Dongguan Tiantianxiangshang Medical Technology Co., Ltd.Biodegradable stent formed with polymer-bioceramic nanoparticle composite and preparation method thereof
Classifications
U.S. Classification264/430, 264/6, 424/423, 623/1.11
International ClassificationB29B9/08, A61F2/00
Cooperative ClassificationY10S977/931, Y10S977/831, A61L31/148, A61L31/128, A61F2/82, Y10S977/776, B29C47/0014, Y10S977/753, B29C47/0021, B29C47/0023, B29C47/0007, A61L31/127
European ClassificationA61L31/12D6, A61L31/14K, A61L31/12D4
Legal Events
DateCodeEventDescription
1 Jun 2007ASAssignment
Owner name: ABBOTT CARDIOVASCULAR SYSTEMS INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, YUNBING;GALE, DAVID C.;REEL/FRAME:019374/0142;SIGNING DATES FROM 20070522 TO 20070525